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Research & developmenta b s t r a c t
Zika virus, influenza, and Ebola have called attention to the ways in which infectious disease outbreaks
can severely – and at times uniquely – affect the health interests of pregnant women and their offspring.
These examples also highlight the critical need to proactively consider pregnant women and their off-
spring in vaccine research and response efforts to combat emerging and re-emerging infectious diseases.
Historically, pregnant women and their offspring have been largely excluded from research agendas and
investment strategies for vaccines against epidemic threats, which in turn can lead to exclusion from
future vaccine campaigns amidst outbreaks. This state of affairs is profoundly unjust to pregnant women
and their offspring, and deeply problematic from the standpoint of public health. To ensure that the needs
of pregnant women and their offspring are fairly addressed, new approaches to public health prepared-
ness, vaccine research and development, and vaccine delivery are required. This Guidance offers 22 con-
crete recommendations that provide a roadmap for the ethically responsible, socially just, and respectful
inclusion of the interests of pregnant women in the development and deployment of vaccines against
emerging pathogens. The Guidance was developed by the Pregnancy Research Ethics for Vaccines,
Epidemics, and New Technologies (PREVENT) Working Group – a multidisciplinary, international team
of 17 experts specializing in bioethics, maternal immunization, maternal-fetal medicine, obstetrics, pedi-
atrics, philosophy, public health, and vaccine research and policy – in consultation with a variety of exter-
nal experts and stakeholders.
 2019 Pan American Health Organization. Published by Elsevier Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).sponding
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Biomedical advancements have brought us tremendous innova-
tions in the past century, yet there has long been a gender problem
– in the ways we understand disease presentation, in the ways we
pursue development of new drugs and biologics, and ultimately in
the ways science and medicine address the health needs of women.
In the 1990s, prominent reports brought to light the extent to
which the interests of women were underrepresented in biomedi-
cal research efforts and the harms associated with their inadequate
inclusion in the research agenda. One of us (RF) was the co-chair of
the Institute of Medicine committee that authored an influential
report of that period, Women and Health Research: Ethical and Legal
Issues of Including Women in Clinical Studies.
Much progress has been made in the last two decades to better
address the health needs of women. However, one recommenda-cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
redness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccintion of that IOM report, specific to pregnant women, gained little
traction. More than twenty years later, tremendous evidence gaps
about the appropriate dosing and use of drugs and biologics in
pregnancy persist. Despite the fact that most women need some
form of medication during their pregnancy – for chronic and acute
conditions – the vast majority of drugs that have come to market
have little to no data on their safe and effective use in pregnancy.
This state of affairs is unacceptable. A new paradigm must be
forged to safely and responsibly include pregnant women in
research so that all pregnant women and their developing children
will ultimately benefit from interventions critical to their health
and wellbeing.
In the mid-20000s, three of us (AL, ML, & RF) began a collabora-
tive research program to change the status quo and forge this new
paradigm. In 2009, we launched the Second Wave Initiative, a col-
laborative academic effort to advocate for, and help find, ethicallywomen & vaccines against emerging epidemic threats: Ethics guidance for
e.2019.01.011
C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx 3and scientifically responsible solutions for increasing our knowl-
edge base for the treatment of pregnant women who face medical
illness. In the intervening years, the Second Wave Initiative has
helped galvanize scholarship and advocacy in the United States,
and around the world.
This Guidance has benefited from the Second Wave and other
intersecting collaborations across the years. Several of us, as part
of a larger team, are working on another grant funded by the U.S.
National Institutes of Health, the PHASES project- Pregnancy &
HIV/AIDS: Seeking Equitable Study (PI: AL), which is developing an
ethical framework for research at the juncture of pregnancy, HIV,
and its co-morbidities. In addition, RF and RK have collaborated for
many years on the ethics of vaccine policy and epidemic response.
Workon thepresentGuidancebegan in2016,when theZikavirus
was shining a global spotlight on the devastation that infectious dis-
ease epidemics can cause inpregnancy.We receivedagrant fromthe
Wellcome Trust to provide ethics guidance at the intersection of
pregnancy, vaccines, and emerging and re-emerging epidemic
threats, the PREVENT project — Pregnancy Research Ethics for Vacci-
nes, Epidemics and New Technologies (PI: RF) — addresses research
with pregnant women in the distinctive context of biologics. In our
first year, we focused on the special case of pregnancy and Zika virus
vaccines. The report of the Ethics Working Group on ZIKV Research
and Pregnancy, Pregnant Women and the Zika Virus Vaccine Research
Agenda: Ethics Guidance on Priorities, Inclusion, and Evidence Genera-
tion, was released in June 2017.
We are delighted now to be releasing our second Guidance,
Pregnant Women & Vaccines Against Emerging Epidemic Threats:
Ethics Guidance for Preparedness, Research, and Response, authored
by the PREVENT Working Group.
This Guidance benefits enormously from the Zika Report and
from the on-going work on PHASES. Further, much of the founda-
tional thinking about pregnant women, fairness and equity, and
research ethics in both PREVENT and PHASES draws on the com-
mon foundation of the Second Wave Initiative.
Across all this work is the shared theme that pregnant
women cannot be ignored as the scientific and biomedical commu-
nities continue to innovate and develop new medicines and tools
to improve health. This Guidance forms a key piece in an important
and growing body of work, by us and by others, to ensure that
pregnant women benefit fairly from advances in biomedicine.
Ruth Faden, Ruth Karron, Carleigh Krubiner,
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AE Adverse Events
AEFI Adverse Events Following Immunization
AVAREF African Vaccine Regulatory Forum
BARDA U.S. Biomedical Advanced Research and
Development Authority
CDC U.S. Centers for Disease Control and Prevention
CEPI Coalition for Epidemic Preparedness Innovations
CIOMS Council for International Organizations of Medical
Sciences
CNAEFIS Chinese National AEFI Information System
DCVRN Developing Country Vaccine Regulators’ Network3 We use the term ‘‘women” throughout this document, and while we appreciateDSMB Data Safety Monitoring Boards
that individuals who do not identify as women can still become pregnant,EMA European Medicines Agency
transgender and gender non-conforming individuals face different (though alsoFDA U.S. Food and Drug Administration
substantial and problematic) barriers to participating in clinical research and havingGAIA
their health needs met that lie beyond the scope of this work. We use the term
‘‘offspring” throughout this report to broadly refer to fetuses as well as any personsGlobal Alignment of Immunization safety
Assessment in Pregnancyborn whose interests may be affected by in utero exposures to pathogens or vaccine
ad
article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant w
research, and response, Vaccine, https://doi.org/10.1016/j.vaccine.2Gaviministrations.
omen & vacci
019.01.011Gavi, the Vaccine Alliance (formerly Global
Alliance for Vaccines and Immunisations)GBS Group B Streptococcus
GBS Guillain-Barré Syndrome
HHS U.S. Department of Health and Human Services
JPEG Proposed WHO Joint Pregnancy Expert Group on
Maternal Immunization
JTEG WHO Joint Technical Expert Group (JTEG) on
Malaria Vaccines in Pivotal Phase 3 Evaluation
LMIC Low- and Middle-Income Countries
MDGs Millennium Development Goals
MNCAH Maternal, Newborn, Child, and Adolescent Health
MSF Médecins Sans Frontières
NIH U.S. National Institutes of Health
NITAG National Immunization Technical Advisory Groups
NRA National Regulatory Authority
ORWH NIH Office of Research on Women’s Health
PAHO Pan American Health Organization
PANDRH Pan American Pharmaceutical Regulation
Harmonization Network
PASS Post-Authorization Safety Studies
PPC Preferred Product Characteristics
PREVENT Pregnancy Research Ethics for Vaccines, Epidemics,
and New Technologies
PRISM Post-Licensure Rapid Immunization Safety
Monitoring
R&D Research and Development
RITAG Regional Immunization Technical Advisory Groups
RSV Respiratory Syncytial Virus
SAGE WHO Strategic Advisory Group of Experts (SAGE)
on Immunization
SDGs Sustainable Development Goals
STAGE Proposed WHO Strategic Technical Advisory Group
of Experts on MNCAH
Tdap Tetanus-diphtheria-acellular pertussis
TPP Targeted Product Profile
UNICEF United Nations Children’s Fund
VAERS U.S. Vaccine Adverse Event Reporting System
WHO World Health Organization
ZKV Zika VirusEXECUTIVE SUMMARY
Recent epidemics, including Zika virus, Lassa Fever, Ebola, and
H1N1 influenza, have highlighted the ways in which infectious dis-
ease outbreaks can severely – and at times uniquely – affect the
health interests of pregnant women and their offspring.3 For some
pathogens, pregnant women are at significantly higher risk of seri-
ous disease and death. Infection in pregnancy can also result in preg-
nancy loss or severe congenital harms. Even if the disease caused by
the pathogen is no worse in pregnancy, the harms of infection in
pregnant women can potentially affect two lives.
These serious and often disproportionate risks underscore the
critical need to proactively consider the interests of pregnantnes against emerging epidemic threats: Ethics guidance for
4 C.B. Krubiner et al. / Vaccine xxx (xxxx) xxxwomen and their offspring in efforts to combat epidemic threats.
This is especially true for vaccines, essential tools in the public
health response to infectious diseases. Despite increasing support
of maternal immunization strategies and efforts to develop certain
vaccines specifically targeted to pregnant women, the vast major-
ity of new vaccine products are rarely designed with pregnant
women in mind. Moreover, widespread failure to appropriately
include pregnant women in vaccine research means that evidence
about safety and efficacy in pregnancy has been limited and late in
coming. As a result, in numerous outbreaks and epidemics, preg-
nant women have been denied opportunities to receive vaccines
that would have protected them and their offspring from the rav-
ages of these diseases.
This way of treating pregnant women in vaccine research and
deployment is not acceptable. Business as usual can no longer
continue.
To ensure that the needs of pregnant women and their offspring
are fairly addressed, new approaches to public health prepared-
ness, vaccine research and development (R&D), and vaccine deliv-
ery are required. This Guidance provides a roadmap for the
ethically responsible, socially just, and respectful inclusion of the
interests of pregnant women in the development and deployment
of vaccines against emerging pathogens. The Guidance is a product
of the Pregnancy Research Ethics for Vaccines, Epidemics, and New
Technologies (PREVENT) Working Group — a multidisciplinary,
international team of 17 experts specializing in bioethics, maternal
immunization, maternal-fetal medicine, obstetrics, pediatrics, phi-
losophy, public health, and vaccine research and policy — in con-
sultation with a variety of external experts and stakeholders.
We recognize the recommendations contained in this Guidance
will not always be easy to follow. For some, it will require a new
way of thinking about pregnant women and vaccines. For many,
it will require a commitment of will and of financial resources.
Addressing inequities in biomedical research and public health
rarely comes cheaply or without hard work. In terms of the lives
saved and the suffering averted, the resources and the effort
needed to ensure that pregnant women and their offspring are
treated fairly will be more than worth it.
VISION
The guidance aims to realize a world in which:
 Pregnant women are not unjustifiably excluded from participat-
ing in vaccine studies.
 Pregnant women and their offspring benefit from advances in
vaccine technologies and are not left behind as new vaccine
products are developed.
 Pregnant women have access to safe and effective vaccines to
protect them and their offspring against emerging and re-
emerging pathogenic threats.
Recommendations
Public health emergency preparedness
Recommendation 1. Health information systems and infectious
disease surveillance systems should be strengthened and inte-
grated to ensure that data relevant to maternal, obstetric, and
newborn health outcomes can inform scientific and public health
responses to emerging pathogenic threats.
 Directed to: public health authorities; the World Health Orga-
nization (WHO) and regional health organizations; developers
and users of routine health information and global health secu-
rity systems, including organizations with a focus on maternalPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinand child health outcomes; organizations developing innova-
tive approaches to data collection and surveillance; funders
and sponsors of maternal health studies and global health
surveillance
Routine health information systems and infectious disease
surveillance systems are both essential to an appropriate and rapid
response to emerging pathogenic threats. Collecting baseline data
on maternal, obstetric, and newborn health can advance the inter-
ests of pregnant women and their offspring by enabling detection
of increases in adverse events that may signal the presence of
infectious disease threats. These baseline rates are also needed to
help interpret whether adverse events surrounding pregnancy
have any causal link to vaccination. Infectious disease surveillance
systems should routinely include pregnancy status and maternal,
obstetric, and newborn outcomes in case reports. These data, when
integrated with baseline rates from health information systems,
can help determine whether a circulating pathogen causes addi-
tional or more severe harms in pregnancy.
Recommendation 2. Evidence-based strategies to promote confi-
dence about vaccination in pregnancy should be developed and
implemented ahead of outbreaks, including stakeholder engage-
ment with health care providers, women, their families, and their
communities.
 Directed to: public health authorities; healthcare providers;
professional medical associations; medical and health training
programs; community leaders; civil society organizations and
vaccine advocacy groups; research institutes; funders and spon-
sors; the media
For immunization programs to be successful, it is critical that
populations have confidence in the benefits of a vaccine and its
safety, and in the health benefits of vaccination more broadly.
Inadequate confidence in vaccines can be especially pronounced
among pregnant women and those who care for them. Evidence
about safety in pregnancy is limited because of the historic absence
of vaccine trials in pregnant women. Moreover, pregnant women
and health care providers are understandably concerned about
fetal harm, and they are frequently bombarded with mixed mes-
sages about what may or may not be harmful in pregnancy. Work-
ing now to better understand and address the various sources and
drivers of vaccine confidence among pregnant women and their
communities will be critical to ensure appropriate vaccine uptake
by pregnant women during outbreaks and epidemics.
Recommendation 3. Communication plans should be developed
for clear, balanced, and contextualized dissemination of vaccine
study findings, recommendations for vaccine use in pregnancy, and
any pregnancy-specific adverse events.
 Directed to: clinical investigators; scientific journal editors;
funders and sponsors; public health authorities; global, regio-
nal, and local vaccine advisory groups; professional medical
associations; regulatory authorities; civil society organizations
and vaccine advocacy groups; the media
Because pregnant women, health providers, and the public
often overestimate potential fetal harms associated with medica-
tions and biologics, effective communication in vaccine develop-
ment and delivery is critical. In research studies, the required
timely reporting of clinically relevant signals and findings on vac-
cine safety and efficacy in pregnancy to regulatory authorities is
not enough. Effective communication to the public and to clini-women & vaccines against emerging epidemic threats: Ethics guidance for
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media, is essential. In an epidemic response that recommends vac-
cination in pregnancy, communication plans must be clear about
any known risks to pregnant women and their offspring, and
why the anticipated benefits of vaccination outweigh these risks.
When immunization in pregnancy is not recommended, communi-
cation plans should be sensitive to fears and concerns about the
pathogenic threat that pregnant women share with the rest of
the population, and provide them with information about what
alternatives, if any, are available to them. In both research and epi-
demic responses, one best practice for communicating reports of
adverse pregnancy or birth outcomes is to present the findings
alongside the best available information about the baseline rates
of these adverse events, and to acknowledge that many of them
have no known cause.
Recommendation 4. Research efforts that aim to advance vaccine
development by using new technologies to study human immune
system function and response should include investigations
specific to pregnant women and their offspring.
 Directed to: clinical investigators; basic research scientists;
funders
Because pregnancy can alter immune response and because
both maternal and fetal immune responses may change over the
course of gestation, it is important that these foundational studies
examine the distinctive characteristics of maternal and fetal
immune systems. Understanding these differences could critically
inform the development and identification of new vaccines that
are safe and effective in pregnancy.
Recommendation 5. Mechanisms for incentivizing vaccine devel-
opment for emerging and re-emerging infections and mitigating
existing disincentives should include and address pregnancy-
specific concerns of vaccine developers.
 Directed to: policymakers; regulatory authorities; funders and
sponsors; vaccine developers; civil society organizations and
those who are positioned to influence vaccine research, adop-
tion, and delivery, including WHO, the World Economic Forum,
and the Coalition for Epidemic Preparedness Innovations (CEPI)
Vaccine developers and manufacturers face significant market
challenges and uncertainties in pursuing products targeting
emerging and re-emerging pathogens. These challenges can
become even more complicated when vaccine products are studied
in and ultimately offered to pregnant women – for whom there
may be heightened concerns of legal and financial liability. Current
mechanisms in place to encourage development of beneficial
biomedical products and protect developers and manufacturers
against liability concerns – as well as new incentive programs
being explored for vaccines against epidemic threats – need to be
intentionally inclusive of the needs and interests of pregnant
women.
Recommendation 6. To help ensure systematic and enduring
change in the treatment of pregnant women in global vaccine
policy and practices, the World Health Organization should
convene a consultation of relevant stakeholders and experts. The
Consultation should identify specific strategies to establish for
pregnant women the presumption of inclusion in both vaccine
research and deployment, including whether a dedicated, standing
expert group is needed.Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinThe Presumptive Inclusion of Pregnant Women
‘‘Presumption of inclusion” does not entail the automatic or
absolute inclusion of pregnant women in every vaccine study
or every vaccine campaign. Instead, a presumption of
inclusion changes the default position. It normalizes the
position that pregnant women are to be included in vaccine
deployment programs and vaccine research and development.
With inclusion of pregnant women as the default position, the
burden of proof, both scientific and ethical, falls on those who
want to argue for their exclusion. There will certainly be cases
where the exclusion of pregnant women from a particular
vaccine trial or vaccine campaign will be justified, but starting
from a presumption of inclusion helps instantiate and
maintain a fundamental shift in the way pregnancy and
pregnant women are viewed in the field of vaccines.
Throughout this Guidance we make multiple recommendations to
help ensure that pregnant women and their offspring can fairly ben-
efit from the protection that vaccines offer against emerging epi-
demic threats. These recommendations outline specific actions
that need to be taken, but institutional change at every level —
globally, regionally, and nationally — will be required to opera-
tionalize these new approaches and move advisory and decision-
making bodies toward the new default of presumptive inclusion
of pregnant women. To seed this institutional change and explore
specific strategies for the systematic consideration of pregnant
women in international policies and practices governing vaccine
research and delivery, WHO should convene a multi-day, global
Consultation of relevant stakeholders. The Consultation should pro-
vide a critical opportunity to discuss and determine the best strate-
gies to systematically integrate consideration of the interests of
pregnant women and their offspring throughout all relevant
WHO-supported activities, including whether a dedicated, standing
group of relevant and diverse experts is needed. The Consultation
should also consider ways to support regional and national public
health authorities who may wish to establish similar expert groups.
Vaccine research & development
Recommendation 7. Suitability for use in pregnancy should be a
strong consideration in development and investment decisions for
vaccines against emerging pathogenic threats.
 Directed to: CEPI, U.S. Biomedical Advanced Research and
Development Authority (BARDA), and other funders and spon-
sors; WHO emergency response teams, R&D Blueprint teams
and TPP Working Groups; vaccine developers
If pregnant women, and the offspring they carry, are among
those threatened by an emerging pathogen, then suitability for
use during pregnancy should be an important vaccine develop-
ment priority. Organizations investing in the vaccine pipeline
against emerging pathogenic threats should try to ensure that,
among candidates prioritized for development, at least some use
platforms and adjuvants that would make them suitable for use
in pregnancy. Early investment in options that are most likely to
be acceptable in pregnancy can pave the way for pregnant women
and their offspring to realize benefits from vaccine candidates that
ultimately prove successful – and help ensure that they, like other
population groups, will be protected against emerging infectious
diseases. For pathogens that pose significantly greater threats in
pregnancy – of fetal harm, maternal harm, or both – funding callswomen & vaccines against emerging epidemic threats: Ethics guidance for
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be suitable for use in pregnancy. When pregnant women or their
offspring are at higher risk of harm, it would be particularly unjust
for their needs not to be included in development priorities.
Recommendation 8. When pathogens pose a risk of severe harm
to pregnant women or their offspring and the most promising
vaccine candidates are likely to be contraindicated for routine use
in pregnancy, investments should be made in alternative vaccine
candidates that could be more readily used in pregnancy.
 Directed to: CEPI, BARDA, and other funders; vaccine
developers
It is possible that the vaccine candidates that move most rapidly
through the R&D pipeline are found to be problematic for use in
pregnancy. Unless other vaccines with more favorable profiles for
use in pregnancy are then prioritized, it is possible that pregnant
women and their offspring will end up without any vaccine protec-
tion against the emerging pathogenic threat. This prospect is par-
ticularly dire when the target pathogen has more severe
consequences in pregnancy. When pregnant women and their off-
spring suffer disproportionately compared to other population
groups from an emerging infectious disease threat, justice calls
for the vaccine enterprise to make every reasonable effort to bring
to market a safe and effective product that pregnant women can
use.
Recommendation 9. Non-clinical studies that are a prerequisite
for clinical trials in pregnant women, such as developmental
toxicology studies, should be initiated early in the clinical devel-
opment of promising vaccine candidates, before efficacy trials are
planned.
 Directed to: CEPI, BARDA, and other funders and sponsors; vac-
cine developers; national regulatory authorities
Current regulatory guidance often requires that certain non-
clinical studies must be completed prior to including pregnant
women in clinical trials. Because pregnant women should be able
to participate in large-scale efficacy studies conducted during out-
breaks whenever the benefits outweigh the risks (see Recommenda-
tion 11), any non-clinical studies required prior to clinical
evaluation in pregnant women should be conducted as soon as
promising vaccine candidates move from phase 1 to phase 2 clini-
cal trials.
Recommendation 10. Studies to assess immune responses to
vaccines in pregnancy should be conducted before or between
outbreaks whenever scientifically possible and ethically and
legally acceptable.
 Directed to: CEPI, BARDA, and other funders and sponsors; vac-
cine developers; clinical investigators
Although much of the work to evaluate vaccines in pregnancy
will be done during outbreaks and epidemics (see Recommendation
11), there will be some cases in which it will be both beneficial and
feasible to generate immunogenicity data in pregnancy before or
between outbreaks. Because immune system functioning is altered
in pregnancy, it is possible that a vaccine will be less immunogenic
or induce atypical immune responses in pregnant women, with
potential implications for its effectiveness as well as the dosing
and frequency required in pregnancy to generate sufficient protec-
tion. Such immunogenicity studies would be particularly valuablePlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinif a correlate of protection for the vaccine has already been estab-
lished. In the absence of an outbreak or epidemic, it may be diffi-
cult to demonstrate that studies to assess immune response in
pregnant women have a favorable risk–benefit profile. However,
there may be instances in which the future exposure to a pathogen
among a particular population is likely enough to conclude that the
potential benefits of being protected would outweigh the risks
associated with a particular candidate vaccine.
Recommendation 11. Clinical development plans for investigational
vaccines against emerging and re-emerging pathogens should include
studies designed to evaluate vaccines in pregnancy. Pregnant women
should have opportunities to enroll in vaccine studies conducted
during outbreaks and epidemics whenever the prospect of benefit
outweighs the risks to pregnant women, their offspring, or both.
 Directed to: CEPI, BARDA, and other funders and sponsors; vac-
cine developers; clinical investigators and trial implementation
partners; research ethics committees; national regulatory
authorities
This recommendation rests on two claims of justice about the
importance of treating pregnant women and their offspring fairly
in the conduct of research on vaccines for emerging and re-
emerging infections. The first of these justice claims pertains to
pregnant women as a class: as a matter of equity, as well as public
health, the evidence base for pregnant women should be as good as
possible and generated as contemporaneously as possible to the
evidence garnered for the population. The second, independent
reason motivated by justice is that pregnant women, as the moral
equals of others, should have fair access to the prospect of direct
benefit that may ensue from receiving an experimental vaccine.
For both of these reasons, it is critical that vaccine research con-
ducted during outbreaks include appropriate plans for research
with pregnant women when there is a reasonable judgment that
the prospective benefits of enrollment outweigh the risks.
Recommendation 12. Vaccine studies that include women of child-
bearing potential should have plans to systematically collect data on
immunogenicity and pregnancy-specific indicators of safety from
participants who are unknowingly pregnant at the time of exposure or
become pregnant within a relevant window following vaccine
administration.
 Directed to: CEPI, BARDA and other funders and sponsors; vac-
cine developers; clinical investigators and trial implementation
partners; research ethics committees; national regulatory
authorities
In trials enrolling women of childbearing potential, including
vaccine trials conducted in outbreak contexts, it is predictable that
some women not known to be pregnant at the time of enrollment
will nevertheless be pregnant at enrollment, or become pregnant
in the course of the trial. Historically, data from inadvertent expo-
sures during pregnancy have been a key source of information
regarding the safety profiles of vaccines in pregnancy. Having a plan
to systematically generate evidence from participants who are
unknowingly pregnant at the time of administration also enables
capturing data from vaccine exposures earlier in pregnancy than
would be likely in trials prospectively enrolling pregnant women.
Wherever possible, systematic observational studies that are
designed to capture inadvertent exposures to vaccine during preg-
nancy should also include longitudinal evaluation of safety,
immunogenicity, and other relevant outcomes. Data from inadver-
tent exposures during pregnancy should be collected using stan-women & vaccines against emerging epidemic threats: Ethics guidance for
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preted, particularly when adverse events occur in early pregnancy,
as these very commonly occur unrelated to vaccine exposure.
Recommendation 13. Women participating in vaccine trials who
become aware of a pregnancy during the trial should be guaranteed
the opportunity, through a robust re-consent process, to remain in the
trial and complete the vaccine schedule when the prospect of direct
benefit from completing the schedule can reasonably be judged to
outweigh the incremental risks of receiving subsequent doses.
 Directed to: clinical investigators and trial implementation
partners; vaccine developers; research ethics committees;
national regulatory authorities
In vaccine trials that include prospectively enrolled pregnant
women, participantswho become pregnant after enrollment should
be provided the opportunity to continue to receive vaccine doses
after a renewed consent process. In trials that exclude pregnant
women from prospective enrollment, determinations about contin-
ued dosing should be based on assessment of the potential benefits
and harms specific to the circumstances of the pregnant participant,
including possible risks associated with receiving an incomplete
vaccination series and the risks already incurred from the first vac-
cination. In both cases, a robust re-consent process will be essential
to allowing pregnant women to determine whether they want to
receive additional doses. Regardless of whether they choose or are
permitted to continue with the vaccine schedule, participants who
become pregnant should be provided all study-related benefits
and ancillary care to which they would otherwise be entitled.
Recommendation 14. When a pregnant woman of legal standing to
consent is judged eligible to enroll or continue in a vaccine trial, her
voluntary and informed consent should be sufficient to authorize her
participation.
 Directed to: clinical investigators and trial implementation
partners; research ethics committees; national authorities in
charge of governance and oversight of human subjects research
As a matter of respect, and as a key aspect of ensuring fair
access to investigational vaccines, the consent of pregnant women
who are judged eligible to participate in or continue receiving
doses in a vaccine trial should be sufficient for participation. Preg-
nant women are the moral equals of other self-governing adults.
Further, requiring the consent of additional actors can present a
material barrier to the benefits research may offer to the offspring.
At the same time, researchers should support pregnant women
who wish to involve partners, family members, and other personal
supports in decisions to join or remain in vaccine trials.
Recommendation 15. Experts in maternal and perinatal health,
pediatrics, and research ethics should be involved in decisions about
funding; trial design; research ethics oversight; and the generation,
analysis, and evaluation of evidence on vaccine use in pregnancy.
 Directed to: funders and sponsors; vaccine developers; clinical
investigators; research ethics committees; national health
authorities in charge of research governance and regulations;
data safety monitoring boards
Pregnant women deserve that decisions affecting them will be
made in careful, thoughtful, and evidence-based ways, involving
the most informed experts possible. Experts in obstetrics and gyne-
cology, maternal-fetal medicine, pediatrics, and neonatology, espe-Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccincially those who have experience with infectious diseases,
immunology, and maternal immunization, have specialized knowl-
edge that is critical to properly identifying and addressing the
needs and interests of pregnant women and their offspring in
research and development.
Recommendation 16. Whenever possible, the perspectives of preg-
nant women should be taken into account in designing and imple-
menting vaccine studies in which pregnant women are enrolled or in
which women enrolled may become pregnant.
 Directed to: clinical investigators; vaccine developers; research
ethics committees; community advisory boards; funders and
sponsors; public health authorities
Community engagement and participatory-based approaches to
biomedical research have been increasingly recognized as good
practice in the design and conduct of human subjects research. In
the context of vaccine studies enrolling pregnant women, soliciting
theperspectives of pregnantwomen fromthe communities inwhich
the research will be conducted offers a way to demonstrate respect,
and canbe critical to the success of a study. The perspectives of preg-
nant women can improve various aspects of study design, including
determiningwhat information and outcomes aremost important to
pregnantwomen, ascertaining culturally relevant considerations for
the consent process, and establishing the appropriate frequency and
location of study visits based on the daily demands onwomen’s lives
throughout pregnancy and after delivery.
Vaccine delivery during the epidemic response
Recommendation 17. Pregnantwomen should be offered vaccines as
part of an outbreak or epidemic response. Pregnant women should only
be excluded if a review of available evidence by relevant experts
concludes that the risks to pregnantwomen and their offspring from the
vaccine are demonstrably greater than the risks of not being vaccinated.
 Directed to: public health authorities; national immunization
programs; recommending and advisory bodies, including pro-
fessional medical associations, SAGE, and other relevant WHO
advisory committees; teams overseeing the epidemic response,
such as Public Health Emergency Operations Centers and inci-
dent management teams; organizations involved in vaccine
delivery in the outbreak response, including UNICEF, MSF, and
International Federation of Red Cross
Because pregnant women are the moral equals of others, and
because there is nothing about being pregnant that would make
them or their offspring less susceptible to the harms of emerging
pathogenic threats, the default position of advisory bodies and
public health authorities should be that pregnant women are
offered vaccines alongside other affected populations during an
epidemic response. Any recommendations or decisions not to use
vaccines in pregnancy during an outbreak or epidemic requires jus-
tification of exclusion based on a reasonable determination that
the risks to pregnant women and their offspring from vaccination
are demonstrably greater than the likely benefits of being pro-
tected from the pathogen. This determination should be made by
relevant experts, including those in maternal, perinatal, and pedi-
atric health. The absence of evidence and the mere theoretical or
even documented risk of fetal harm is generally not sufficient to
justify denying pregnant women access to a vaccine in an out-
break or epidemic. Even when the risk of fetal harm from the vac-
cine is significant, if the likelihood and severity of harms from thewomen & vaccines against emerging epidemic threats: Ethics guidance for
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then the benefits of vaccination may still outweigh the risks.
Recommendation 18. When there is a limited supply of vaccine
against a pathogenic threat that disproportionately affects pregnant
women, their offspring, or both, or when only one vaccine among
several is appropriate for use in pregnancy, then pregnant women
should be among the priority groups to be offered the vaccine.
 Directed to: public health authorities; national immunization
programs; teams overseeing the epidemic response, such as
Public Health Emergency Operations Centers and incident man-
agement teams; WHO; organizations involved in vaccine deliv-
ery as part of the outbreak response, including UNICEF, MSF,
and International Federation of Red Cross
It is not uncommon in outbreak and epidemic settings for vac-
cine demand to exceed supply. For some pathogenic threats, preg-
nant women and their offspring may be among the hardest hit
groups; in these cases, as with any other high-risk group, they
should be a priority in the allocation of a vaccine that is in short
supply. Additionally, even when the threat is no worse for preg-
nant women than it is for other affected population groups, vacci-
nating a pregnant woman protects not only the pregnant woman
but also her offspring. Particularly for high-consequence pathogens
with significant mortality rates, there may be considerable addi-
tional benefit in vaccinating pregnant women.
Recommendation 19. When vaccines are offered to pregnant
women in outbreaks or epidemics, prospective observational studies
should be conducted with pregnant women and their offspring to
further advance the evidence base for use in pregnancy.
 Directed to: vaccine manufacturers; public health and regula-
tory authorities; national immunization programs; organiza-
tions involved in vaccine delivery as part of the outbreak
response, including UNICEF, MSF, and International Federation
of Red Cross; researchers; funders; groups that oversee research
with human subjects, including research ethics committees
Implementing prospective observational studies in pregnant
women and their offspring who receive the vaccine as part of the
outbreak or epidemic response provides an important opportunity
to narrow the evidence gap between pregnant women and other
population groups. If such studies are not conducted, decision-
makers in future outbreaks and epidemics will be faced with the
same evidence gap as current decision makers – an unacceptable
outcome from both an equity and a public health perspective.
Moreover, safety data obtained from evaluating a vaccine derived
using a novel platform in pregnant women may inform future
decision-making regarding the suitability of that platform for
development of vaccines against other pathogens.
Recommendation 20. When vaccines are offered to pregnant
women in outbreaks and epidemics, the consent of the pregnant
woman should be sufficient to authorize administration whenever the
pregnant woman is of legal standing to consent to medical care.
 Directed to: public health authorities; national immunization
programs; teams overseeing the epidemic response, such as
Public Health Emergency Operations Centers and incident man-
agement teams; organizations involved in vaccine delivery as
part of the outbreak response, including UNICEF, MSF, and
International Federation of Red Cross; clinicians and obstetri-
cians; pregnant women and communitiesPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinAs a matter of respect, and as a key aspect of ensuring fair
access to vaccines during an outbreak or epidemic, when vaccines
are offered to pregnant women, their consent should be sufficient
to authorize administration. Women should be presumed to have
authority for decisions about their own medical care. Women are
no different from men in this respect, and pregnant women are
no different than women who are not pregnant. All adults, regard-
less of gender or pregnancy status, have rights of self-
determination over decisions that affect their bodies and their
health. Pregnant women who wish to engage or consult with their
partners or other family or friends in making their decisions about
vaccination should be supported in doing so.
Recommendation 21. When evidence supports a determination that
the risk of serious maternal or fetal harm from the vaccine outweighs
the vaccine’s benefits, pregnant women should be a priority group for
access to alternative preventative or treatment measures.
 Directed to: public health authorities; teams overseeing the
epidemic response, such as Public Health Emergency Opera-
tions Centers and incident management teams; organizations
involved in vaccine delivery as part of the outbreak response,
including UNICEF, MSF, and International Federation of Red
Cross; providers
Despite the best possible research and development efforts, the
available vaccine for a given outbreak or epidemic may have suffi-
ciently severe pregnancy-specific risks, even compared with the
risks posed by the pathogen, that it is not made available to preg-
nant women. The moral objective remains, however, of giving
pregnant women and their offspring as close to an equal chance
of avoiding the harms of infection as the rest of the population. If
they cannot be protected by immunization, then pregnant women,
along with any other population group that cannot receive the vac-
cine, should be given preferential access to alternative preventive
interventions and treatments.
Recommendation 22. When vaccines against emerging pathogens
are not recommended for use in pregnancy, inadvertent vaccine
exposures during pregnancy should be anticipated and mechanisms
put in place for the collection and analysis of data from pregnant
women and their offspring on relevant indicators and outcomes.
 Directed to: public health and regulatory authorities; vaccine
manufacturers; national immunization programs; funders and
sponsors
Even when pregnant women are intentionally excluded from
the vaccine response effort, it is reasonable to expect that some
of the women who are vaccinated will be unknowingly pregnant
at the time of vaccine administration, or will become pregnant
within a relevant window of its administration. Collecting data
about outcomes in these women and their offspring in the midst
of an active outbreak or epidemic will be difficult and costly, but
there are two sets of ethical and public health reasons why it is
critically important to do so. First, collecting data from uninten-
tional exposures to vaccine in pregnancy during an outbreak or
epidemic affords an important opportunity to gather evidence
about novel vaccine technologies and thus to help ensure that
pregnant women are not left behind as vaccine technology
advances. Second, research and public health communities have
a responsibility to pursue evidence about the likelihood and nature
of any associated risks pregnant women and their offspring face
from these unintended exposures to inform personal and clinical
decision-making.women & vaccines against emerging epidemic threats: Ethics guidance for
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This guidance addresses a critical gap in the global vaccine
response to emerging and re-emerging pathogens — the needs of
pregnant women and their offspring.
A century ago, the Spanish Influenza pandemic of 1918–1919
infected nearly a third of the world’s population, killing between
50 and 100 million people [1]. In more recent years, Ebola, Lassa
Fever, and Zika virus have devastated smaller populations. Each
of these epidemics highlights the ways in which infectious disease
outbreaks can severely, and at times uniquely, affect the health
interests of pregnant women and their offspring.4 In the case of
influenza, Ebola, and Lassa Fever, pregnant women are at signifi-
cantly higher risk of serious disease and death than the general pop-
ulation, with potentially devastating consequences for their
offspring [2–4]. For example, Ebola infection in pregnancy not only
poses severe maternal risk of death, but results in near 100% fetal
demise or neonatal death [3]. Other pathogens that cause less severe
disease in healthy adults can have significant associated risks for the
developing fetus. In the wake of the 2016–2017 Zika virus epidemic,
we now know all too well that even pathogens associated with mild
illness in pregnant women can cause devastating congenital harms
[5,6]. Regardless of whether a pathogen poses heightened risks of
disease-associated harms in pregnancy, infection among pregnant
women always has the potential to impact two lives.
These serious and often disproportionate risks underscore the
critical need to proactively consider the interests of pregnant
women and their offspring in efforts to combat epidemic threats.
This is especially true for vaccines, essential tools in the public
health response to infectious diseases.
Despite increasing support for maternal immunization and
efforts to develop certain vaccines specifically targeted to pregnant
women, the vast majority of new vaccine products are rarely
designed with pregnant women in mind [7].5 Moreover, wide-
spread failure to appropriately include pregnant women in vaccine
research means that evidence about safety and efficacy in pregnancy
has been limited and late in coming. As a result, during numerous
outbreaks and epidemics, pregnant women have been denied oppor-
tunities to receive vaccines that would have protected them and
their offspring.
This way of treating pregnant women in vaccine research
and deployment is not acceptable. Business as usual can no
longer continue
To ensure that the needs of pregnant women and their offspring
are fairly addressed, new approaches to public health prepared-
ness, vaccine research and development (R&D), and vaccine deliv-
ery are required.
This Guidance was developed to help advance these new
approaches. It is the product of the Pregnancy Research Ethics for
Vaccines, Epidemics, and New Technologies (PREVENT) Working
Group—a multidisciplinary, international team of 17 experts spe-
cializing in bioethics, maternal immunization, maternal-fetal med-4 We use the term ‘‘women” throughout this document, and while we appreciate
that individuals who do not identify as women can still become pregnant,
transgender and gender non-conforming individuals face different (though also
substantial and problematic) barriers to participating in clinical research and having
their health needs met that lie beyond the scope of this work. We use the term
‘‘offspring” throughout this report to broadly refer to fetuses as well as any persons
born whose interests may be affected by in utero exposures to pathogens or vaccine
administrations.
5 In recent years, there have been increasing efforts develop select vaccines
exclusively targeted to pregnant women to prevent illness in offspring, such as those
against respiratory syncytial virus (RSV) and group B streptococcus. These candidate
vaccines offer promise for the first set of vaccines specifically licensed for use in
pregnancy. However, challenges still persist to ensure adequate inclusion of the
interests of pregnant women in R&D agendas for vaccines targeted to the broader
population.
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research. The Guidance was also informed by broad consultation
with a variety of external experts and stakeholders, as well as
extensive reviews of the scientific literature and academic research
on international ethics guidance and regulations regarding
research with pregnant women. (See Appendix B for more details
on our approach to the development of this Guidance.)
The context for this guidance
The Guidance was developed in the context of three significant
shifts in bioethics and in vaccine science and practice that have the
potential to advance the health interests of pregnant women and
their offspring. The first is increasing global awareness that preg-
nant women have been treated inequitably in health research.
The second is increasing global investment in routine maternal
vaccination for endemic diseases. And the third is increasing global
commitments to epidemic vaccine development and deployment.
There is growing recognition that the failure to attend fairly to
the health interests of pregnant women in biomedical research is
unacceptable. The World Health Organization (WHO), Pan Ameri-
can Health Organization (PAHO), Council for International Organi-
zations of Medical Sciences (CIOMS), American College of
Obstetrics and Gynecology (ACOG), and various U.S. federal agen-
cies are advocating for the inclusion of the interests of pregnant
women and their offspring in biomedical research, as are a increas-
ing number of bioethicists, including several bioethics scholars on
our Working Group (see Preface) [8–17].
Through these significant advances in affirming the importance
of involving pregnant women in research, four ethical principles
have emerged and are presented in Appendix A. Our Guidance
builds on these principles, as well as general principles of public
health ethics, research ethics, and gender equity.
Also important to this Guidance are the substantial efforts cur-
rently being made to advance maternal immunization, which can
protect mother and infant from endemic as well as epidemic dis-
eases. These include efforts to: promote the use of existing vacci-
nes, such as influenza and tetanus-diphtheria-acellular pertussis
(Tdap) vaccines; develop new vaccines that are purpose-built
for maternal immunization, such as those for respiratory syncytial
virus and Group B streptococcus; and to harmonize the assess-
ment of maternal, fetal, and neonatal health outcomes [7,18–
22]. Depending upon the pathogen, these vaccines may prevent
disease in the mother and fetus during pregnancy, and may also
protect the newborn infant through passive transfer of maternal
antibody. The development of our Guidance has benefitted from
the work done to promote routine maternal immunization, and
in turn, we anticipate that some of the recommendations we
articulate in the context of maternal vaccination against emerging
threats will also be applicable to routine maternal immunization
efforts.
Another critical consideration for this Guidance is the increas-
ing global commitment to the ethics of public health prepared-
ness and response in epidemic contexts, and the increasing
global commitment to the development of vaccines to protect
against emerging and re-emerging pathogens that threaten popu-
lations worldwide [8,23–27]. These include new funding mecha-
nisms, research activities, and exploration of ways to streamline
regulatory pathways and to address market disincentives. Nota-
bly, many of these global coordination activities have expressly
included a commitment to equitable access, which the Coalition
for Epidemic Preparedness Innovations (CEPI) has articulated as
ensuring that ‘‘the right vaccines are available when and where they
are needed to end an outbreak or prevent an epidemic, that they are
accessible to all people as necessary to achieve that objective. . ..”
[25,28,29].women & vaccines against emerging epidemic threats: Ethics guidance for
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6 Many co-authors of this guidance and others have published elsewhere on the
multiple factors that have contributed to the widespread exclusion of pregnant
women from biomedical research and the implications of these research gaps for
appropriate management of the clinical needs of pregnant women. One notable
exception occurred during the 2009 influenza pandemic, when H1N1 influenza
vaccines were widely recommended and used during pregnancy, with accompanying
prospective safety and immunogenicity studies. See Box 4 for more on the H1N1
vaccine and pregnancy.
7 By ‘‘accessible” we adopt the ‘‘Five A’s” conception of access introduced by
Penchansky and Thomas in which access entails: availability, affordability, accessi-
bility, acceptability/appropriateness, and accommodation, the latter regarding flex-
ible arrangements for the timing and location of care provision that meet the
circumstances of patients. Others have since added ‘‘sustainable” or ‘‘adequate
supply” to this conception.
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demic preparedness through strengthening health information
systems, surveillance, and the infrastructure needed for detecting
and responding to these health emergencies.
Collectively, these new efforts and investments present critical
opportunities to better meet the needs of pregnant women and
their offspring.
We recognize that it will not be easy to make the most of these
opportunities. For some, it will require a newway of thinking about
pregnant women and vaccines. For many, it will require a commit-
ment ofwill and of financial resources. Advancing justice in biomed-
ical research andpublic health rarely comes cheaply orwithouthard
work. In terms of the lives saved and the suffering averted, the
resources and the effort needed to ensure that pregnant women
and their offspring are treated fairly will be more than worth it.
The Guidance
The Guidance begins by setting forth an aspirational vision and
makes the case for its moral importance. We then specify 22
concrete recommendations, organized around three key areas:
public health preparedness, R&D, and vaccine delivery.
The recommendations are directed at a range of actors,
including global and national policymakers, regional and national
regulatory authorities, funders and sponsors, vaccine manufactur-
ers, research institutions, trial networks and research groups,
individual researchers, oversight bodies, ethics review committees,
community advisory boards, and civil society organizations. Each
recommendation specifies the actors to whom it is directed.
VISION
We envision a world in which:
 Pregnant women are not unjustifiably excluded from participat-
ing in vaccine studies
 Pregnant women and their offspring benefit from advances in
vaccine technologies and are not left behind as new vaccine
products are developed.
 Pregnant women have access to safe and effective vaccines to
protect them and their offspring against emerging and re-
emerging pathogenic threats.
Rationale for the vision
When new or re-emerging pathogens threaten populations, one
of the most often overlooked groups in the vaccine response is
pregnant women. Historically, pregnant women and their offspringPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinhave been largely excluded from research agendas and investment
strategies for vaccines against epidemic threats. They have also
been excluded from the vast majority of vaccine research studies,
including many with favorable risk-benefit profiles, with serious
implications for their future access to safe and effective vaccines
during outbreaks and epidemics [30,31].6
Yet, pregnant women are no less susceptible than other pop-
ulations to the harms of emerging infectious diseases. In fact,
many emerging pathogens have more severe morbidity and mor-
tality in pregnancy, including Lassa Fever, Ebola virus, pandemic
influenza, and Hepatitis E virus. These and others, such as Zika
virus, can also cause fetal loss and significant congenital abnor-
malities. Even when the harms of infection in pregnancy are
similar to those in non-pregnant adults, infection during preg-
nancy adversely affects two lives – the woman and her future
child – not just one.
This state of affairs is profoundly unjust to pregnant women and
their offspring, and deeply problematic from the standpoint of pub-
lic health. When threatened by outbreaks or epidemics, pregnant
women and their offspring are as entitled as any other population
to protection of their health, and in many cases protection is best
afforded by vaccination. The potential public health impact of
excluding pregnant women from vaccination programs is substan-
tial; each year, over 200 million women worldwide are pregnant
[32].
We envision a world in which pregnant women, like other pop-
ulation groups, have safe, effective, and accessible7 vaccines to pro-
tect them and their offspring against emerging and re-emerging
pathogenic threats. To realize this vision, pregnant women will need
to be on the agenda when decisions about investment and funding
are made, and concerted efforts will need to be taken to gather suf-
ficient evidence about the safety and efficacy in pregnancy of vaccine
products and new vaccine technologies.
Several features of the current vaccine landscape work against
the interests of pregnant women. Immunization options for preg-
nant women are currently viewed by many as severely limited,
with only subunit or killed vaccines considered appropriate for
use during pregnancy. Even if several candidates using these cur-
rently ‘‘acceptable” platforms are pursued for an emerging infec-
tious disease, there are no guarantees that any will prove
successful. Moreover, in an emerging epidemic, time matters. Sub-
unit and killed vaccines often require multiple doses over time to
induce protective immunity.
Live attenuated vaccines, by contrast, often require only a single
dose to produce long-lasting immunity. However, live attenuated
vaccines have historically been contraindicated for use in preg-
nancy or advised only in extreme epidemic or bioterrorism threat
contexts. This is because of concerns about the theoretical risk that
a vaccine virus which replicates systemically could cross the pla-
centa to infect the fetus and produce adverse pregnancy and birth
outcomes. For the large majority of live attenuated vaccines,
adverse pregnancy, fetal, and neonatal outcomes have not been
observed (see Box 12), yet there is still widespread reticence towomen & vaccines against emerging epidemic threats: Ethics guidance for
e.2019.01.011
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ence for alternative vaccine platforms.
Novel vaccine technologies, such as nucleic acid-based and viral
vector platforms, represent an increasing part of the vaccine R&D
pipeline for emerging and re-emerging pathogens. These vaccine
platforms may offer significant advantages over other more tradi-
tional platforms, particularly in the face of emergingoutbreaks: they
maybe faster to develop, cheaper tomanufacture, easier to store and
transport, and hold the potential to stimulate broad and durable
immunity. But little is known about their safety in pregnancy. If
pregnantwomenaredeniedaccess to these andothernovel vaccines
because of insufficient evidence about safety, they may only have
access to an inferior vaccine, or worse, to no vaccine at all.
From the standpoints of both equity and public health, this state
of affairs is deeply problematic. Unless evidence is generated about
the safety and efficacy of existing and new vaccine technologies,
unfair and harmful differences in access to vaccines during public
health emergencies between pregnant women and the rest of the
population will only widen.
It is not just womenwho know they are pregnant, but all women
of childbearing potential, who are disadvantaged by the absence of
such evidence. During outbreaks and epidemics, vaccination cam-
paigns will inevitably involve inadvertent exposures for women
whose pregnancy status was unknown at the time of vaccination
orwho become pregnantwithin a relevant timewindowof vaccina-
tion. It is critical forwomen and their clinicians to have the best pos-
sible evidence to understand the implications of such exposures.
Absent such evidence, pregnant women who are inadvertently
exposed to a vaccine may experience unnecessary anxiety, both
about potential harms to their offspring andalso aboutwhether they
can expect the vaccine to protect them from disease.
Ensuring that pregnant women have safe, effective, and accessi-
ble vaccines to protect them and their offspring during outbreaks
and epidemics will require the generation of evidence from preg-
nant women participating in vaccine research. Research with preg-
nant women is morally and technically complex. But as we noted
in the Introduction, there is increasing recognition that research
with pregnant women can be conducted in ethically, scientifically,
and medically responsible ways, and indeed that there is an ethical
and public health imperative to do so. So long as vaccine studies
with pregnant women are not conducted, the evidence needed to
ensure that pregnant women have access to vaccines in public
health emergencies cannot be generated.
Moreover, the exclusion of pregnant women from vaccine trials
conducted in the midst of an imminent threat may unjustifiably
deny themwhat may be the only or best way to protect themselves
and their offspring from that threat [30]. The more dangerous the
pathogen, the more important it is to afford fair opportunity to par-
ticipate in research and ensure access to the potential benefit it may
bring.
In the recommendations that follow, we lay out a path towards
the realization of our vision of a world in which pregnant women
and their offspring will benefit from the best possible vaccines
against emerging and re-emerging pathogens; a world in which
pregnant women are treated fairly and respectfully; and pre-
ventable harms to them and to their offspring are safely averted.
The recommendations fall under three key areas: (I) Preparedness:
activities that should be undertaken as part of public health pre-
paredness in anticipation of outbreaks; (II) R&D: appropriate inclu-
sion of the interests of pregnant women and their offspring in
research and development of vaccines against emerging epidemic
threats; and (III) Vaccine Delivery: ensuring that pregnant women
are appropriately included in vaccine campaigns during active out-
breaks and epidemics.Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
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Public health emergency preparedness
Recommendation 1
Health information systems and infectious disease surveillance
systems should be strengthened and integrated to ensure that data
relevant to maternal, obstetric, and newborn health outcomes can
inform scientific and public health responses to emerging patho-
genic threats.
 Directed to: public health authorities; WHO and regional health
organizations; developers and users of routine health informa-
tion and global health security systems, including organizations
with a focus on maternal and child health outcomes; organiza-
tions developing innovative approaches to data collection and
surveillance; funders and sponsors of maternal health studies
and global health surveillance
Reliable health information systems and reliable surveillance
systems are both essential for an appropriate and rapid response to
emerging pathogenic threats. As countries and partners continue
to invest in strengthening these systems, relevant indicators of
maternal, obstetric, and newborn outcomes must be captured in
each system. As noted in the WHO Guidance for Managing Ethical
Issues in InfectiousDiseaseOutbreaks, it is critical to collect informa-
tion about these indicators to assess potential differences in the risk
of infection,modesof transmission, outcomes, and response to inter-
ventions [8]. It is equally critical that these systems are integrated
with bi-directional communication of data and signals. Unless these
systems can and do effectively ‘‘talk” to each other, preventable
harms to pregnant women and their offspring are likely to occur.
Collecting data on maternal, obstetric, and newborn health can
advance the interests of pregnant women and their offspring in at
least three ways. First, having baseline rates of specific outcomes
in pregnancy and the post-partum period can enable detection of
significant increases in adverse maternal, fetal, or newborn events
thatmay signal the presence of infectious disease threats as a possi-
ble causal factor. This capacity is especially important for pathogens
associated with unique or severe manifestations in pregnancy. For
instance, significant increases in certain congenital malformations
likemicrocephaly could signal the presence of circulating Zika virus.
Second, when surveillance activities have already detected a
circulating pathogen in the population, baseline data on maternal,
obstetric, and newborn health can help determine whether the
pathogen is causing additional or more severe pregnancy-specific
harms – but only if infectious disease surveillance systems also
capture relevant indicators. If information is not collected on preg-
nancy status or pregnancy outcomes in surveillance case reports, it
will be difficult if not impossible to assess differential morbidity
and mortality among pregnant women or differential fetal impacts.
For instance, the lack of pregnancy-specific data captured in Ebola
surveillance efforts presented challenges to the accurate assess-
ment of the burden of Ebola virus disease in pregnancy [33,34].
Third, having background rates of maternal, pregnancy, and
neonatal outcomes can help in assessing potential risk relation-
ships between vaccination and adverse events. Without reliable
background rates, it will be difficult to interpret potential safety
signals in a vaccine trial or in a vaccine program, and thus difficult
to determine whether there is sufficient reason to caution against
the use of the vaccine in pregnancy. Based on an event that might
be unrelated to vaccination but relatively common in pregnancy
(e.g., early pregnancy loss), pregnant women who would otherwise
be trial participants could be excluded, perhaps without justifica-women & vaccines against emerging epidemic threats: Ethics guidance for
e.2019.01.011
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be removed from the study, after which they might experience
substantial unwarranted anxiety, in some cases leading them to
terminate a pregnancy from fear of harm. Moreover, if the vaccine
trial is successful and the vaccine is deployed against a looming
outbreak or epidemic, pregnant women and their offspring could
be denied the benefits of vaccine protection based upon false safety
signals. Similarly, if pregnant women are offered vaccine during an
outbreak or epidemic and adverse events in pregnancy begin to be
reported, the inability to interpret the clinical significance of these
events could result in a situation in which pregnant women unnec-
essarily forego and are advised against beneficial immunizations
out of unsubstantiated fears of vaccine-associated harms [35,36].
Coordination and integration between the systems capturing
adverse pregnancy and birth outcomes and those assessing patho-
genic threats can also be helpful in weighing the relative risks of
potential congenital harms related to vaccination and those related
to infection with the circulating pathogen [37–40]. When little is
known about a pathogen’s effects in pregnancy, additional case
series and prospective cohort studies may be critically important
not only for identifying the particular ways in which the disease
presents, but to establish clear and harmonized case definitions
for ongoing surveillance efforts. For example, since the onset of
the Zika epidemic in Latin America, targeted epidemiologic studies
have led to refinement and expansion of the case definition for
congenital Zika syndrome [6,41].
Rates of adverse obstetric and neonatal outcomes should be
contextualized by accessibility and uptake of antenatal care, skilled
birth attendance, and other indicators recognized to improve these
outcomes. Among the more challenging yet important data to
obtain relates to indicators around pregnancy loss (also called mis-
carriage, spontaneous abortion, and stillbirth). Of note, pregnancy
loss in the first trimester is more common than later loss: it is esti-
mated that 80% of pregnancy loss occurs in the first trimester
[42,43]. Yet many early losses are neither recognized nor reported.
The results of several studies and reviews converge at a rate of
early pregnancy loss among clinically recognized pregnancies
ranging from 15 to 20% [44,45]. However, continued surveillance
and refinement of these data are important.
Given these challenges (see Box 1), background rates must be
used with care and should account for the uncertainty in such esti-
mates, including differences in geography, season, ethnicity,
maternal age, and week of gestation, as well as the limitations of
the methods used to determine these rates [35].Box 1. Challenges and opportunities associated with collect-
ing background rates
There are many challenges to collecting data on important
pregnancy-related indicators, including: conflicting, non-stan-
dardized definitions of adverse obstetric and neonatal events;
differential capacities of national or subnational health sys-
tems to detect prevalence of pregnancy-related conditions;
and variability in the prevalence of these events across differ-
ent populations. Rates of adverse outcomes may also vary
across gestation – a detail which may not be captured by rou-
tine information systems – and increasing use of ultrasono-
graphy may lead to higher rates of detection of pregnancies
and of fetal anomalies. Increased use of ultrasonography
may also allow for more frequent assessment of gestational
age, which is critical for the accurate evaluation of many
adverse birth outcomes. An increasing focus on expanding
access to antenatal care (ANC) will likely lead to an increased
detection of obstetric events, particularly as the emphasis is
on expanding such care to underserved populations.Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
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infection such as urinary or upper
respiratory infection, chorioam-
nionitis, puerperal infection,
bleeding and clotting disorders,
pulmonary embolus, and cardio-
vascular morbidity such as peri-
partum cardiomyopathy [46].There are also new opportunities to strengthen these data collection
efforts. Because of the ongoing focus on improving maternal and
infant outcomes in many countries, including in pursuit of the Mil-
lennium Development Goals (MDGs 4&5) and the Sustainable
Development Goals (SDGs), there have already been investments
made to capture some of these data [47]. For example, the Global
Network for Women’s and Children’s Health Research launched a
prospective, population-based registry of pregnancies across 7
low- and middle-income country (LMIC) sites to establish better
reporting systems on important pregnancy and perinatal health
indicators [48]. Significant efforts have been made on behalf of
the Brighton Collaboration and others to harmonize case definitions
of obstetric and neonatal events that could occur in immunization
in pregnancy and/or maternal and child health studies and pro-
grams [49]. Additionally, mHealth technologies and other relevant
apps should be used as needed in systematic data collection efforts.
For example, the U.S. National Institutes of Health (NIH) launched a
crowdsourcing platform called ‘‘Pregsource.” (https://pregsource.
nih.gov)
Recommendation 2
Evidence-based strategies to promote confidence about vaccina-
tion in pregnancy should be developed and implemented ahead
of outbreaks, including stakeholder engagement with healthcare
providers, women, their families, and their communities.
 Directed to: public health authorities; healthcare providers;
professional medical associations; medical and health training
programs; community leaders; civil society organizations and
vaccine advocacy groups; research institutes; funders and spon-
sors; the media
For immunization programs to be successful, it is critical that
populations have confidence in the benefits of a vaccine and its
safety, and in the health benefits of vaccination more broadly.
Much has been written about how inadequate vaccine confidence
leads to suboptimal uptake of safe and effective vaccines [50–
52]. The challenges associated with vaccine confidence can be
especially pronounced among pregnant women and their provi-
ders, given concerns and mixed messaging about potential fetal
harms, the limited data available regarding safety and immuno-
genicity of vaccines in pregnancy, and the well-characterized phe-
nomenon of risk distortion in pregnancy [50,53,54]. Uptake of
widely recommended maternal immunizations has been far below
ideal in both high- and low-income country contexts [53,55–58].erging epidemic threats: Ethics guidance for
C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx 13Unless vaccine confidence among pregnant women and the
health professionals who care for them is enhanced, these sub-
optimal coverage rates will continue. Action is needed now, in
advance of any public health emergency, to develop and imple-
ment evidence-based strategies to increase professional, commu-
nity, and individual confidence in vaccination during pregnancy
in the specific context of outbreaks and epidemics [8].
Where possible, these efforts should both leverage and con-
tribute to ongoing efforts in the context of routine maternal immu-
nization, as it is likely that the drivers of vaccine confidence are
similar. WHO and PATH, with support from the Gates Foundation
and CDC, have already begun to develop resources and guidance
on promoting vaccine confidence among pregnant women, with
a focus on introducing maternal influenza vaccine in low- and
middle-income countries and on planning for introduction of
maternal vaccines in late stage clinical development [59]. Available
resources include a sample protocol for assessing awareness and
acceptance of maternal influenza vaccination among health care
workers, women of childbearing potential, and their spouses
[60]. Other examples of resources include a regional field guide
for maternal and neonatal immunization developed by PAHO and
immunization communications toolkits for providers developed
by ACOG [61,62]. These resources need to be adapted and
expanded upon to address the specific context of outbreaks and
epidemics.
Developing and implementing evidence-based strategies will
require sustained engagement with pregnant women, their health
professionals, and other stakeholders. It will also require an invest-
ment in empirical social science research to better understand the
drivers of vaccine confidence in different cultural settings in the
specific context of pregnancy, outbreaks, and epidemics, as well
as the resources to implement and evaluate evidence-based inter-
ventions that are grounded in this research (see Box 2).Box 2. Determinants of vaccine hesitancy/confidence
There are many drivers of vaccine confidence in general
and in pregnancy more specifically. The WHO SAGE Vaccine
Hesitancy Working Group developed a model of determi-
nants of ‘‘vaccine hesitancy” that was structured around
three domains: (1) contextual influences – including the roles
of religion, culture, gender, and the media environment; (2)
individual and group influences – including personal percep-
tions of vaccine risks and benefits, experiences and interac-
tions with health providers, and influences of family
members and peers; and, (3) vaccine and vaccination-specific
issues – which entail specific aspects related to characteris-
tics of a vaccine and how it is delivered [50,51].
8 For licensed vaccines, there are now new mechanisms in place to include more
nuanced and contextualized evidence and recommendations about vaccine use in
pregnancy on product labels and package inserts, in particular under the Pregnancy
and Lactation Labeling Rule of the FDA.Recommendation 3
Communication plans should be developed for clear, balanced, and
contextualized dissemination of vaccine study findings, recom-
mendations for use in pregnancy, and any pregnancy-specific
adverse events.
 Directed to: clinical investigators; scientific journal editors;
funders and sponsors; public health authorities; global, regional
and local vaccine advisory groups; professional medical associ-
ations; regulatory authorities; civil society organizations and
vaccine advocacy groups; the media
Communication about specific vaccines, their associated risks
and benefits, and recommendations for their use is critical to anPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccineffective outbreak or epidemic response. Nowhere is this more true
than in pregnancy, where risk distortion is a prominent feature of
both professional and personal risk assessment [44,63,64]. Several
strategic risk communication resources for vaccines already exist
and, with adaptation, they can be helpful in improving communi-
cation to mitigate against these pregnancy-specific concerns [65–
69]. Below, we discuss some pregnancy-specific communication
strategies that should be developed for three distinct contexts.
Communicating about vaccine trials and research findings
The need for effective and contextualized communication
begins with early evidence generated in non-clinical studies and
clinical trials. This includes findings from vaccine studies enrolling
pregnant women, vaccine studies with women of childbearing
potential that may have unintended vaccine administrations in
pregnancy, as well as developmental toxicology studies using var-
ious animal models. Because of the likely public interest in any
clinically relevant signals and findings on vaccine safety and effi-
cacy in pregnancy, effective and timely communication to regula-
tory authorities, policymakers, and health care providers, though
critical, is insufficient. Plans must also be developed for effective
communication to the public, including with and through tradi-
tional and social media (see Box 3) [70]. The communication plan
should include any findings suggestive of efficacy and safety in
pregnancy. It should also ensure that findings of adverse events
are contextualized by background rates for these outcomes, as well
as by the potential harms of infection to pregnant women and their
offspring. Communications should also be transparent about the
evidence available regarding use of a particular vaccine in preg-
nancy, given that decisions about use may need to be made rela-
tively early in the clinical development process [54,68,69].
Communicating vaccine recommendations in pregnancy
During outbreaks and epidemics, public health authorities, rec-
ommending bodies, and professional associations will be deter-
mining whether a vaccine should be offered during pregnancy,
and if so, whether the recommendation is specific to pregnancy
trimester. Those making this determination should communicate
the recommendation and the reasons behind it as clearly as possi-
ble to health care providers, affected communities, and pregnant
women [8].
If the recommendation is that pregnant women are offered the
vaccine, the communication plan must be clear about the benefits
of vaccination, any known risks to pregnant women and their off-
spring, and why the anticipated benefits outweigh these risks. In
explaining why the vaccine is recommended for use in pregnancy,
the communication plan should be sensitive to issues of low vaccine
confidence among pregnant women and the communities in which
they live, as well as public anxieties surrounding outbreaks and epi-
demics. The communication plan should also be sensitive to the crit-
ical role that health care providers can play in increasing the
likelihood of vaccine acceptance [71,72]. Health care providers vary
in knowledge and attitudes about vaccination in pregnancy. Dis-
crepancies often exist between health care providers’ awareness of
vaccine recommendations and their adherence to them [73].8
If the recommendation is for pregnant women not to be offered
access to a vaccine, the communication plan should be sensitive to
fears and concerns about the pathogenic threat that pregnant
women share with the rest of the population, and include informa-
tion about what alternatives, if any, are available to pregnant
women who must now face the outbreak or epidemic without ben-
efit of a vaccine to protect them and their offspring.women & vaccines against emerging epidemic threats: Ethics guidance for
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Box 3. Communicating with and through the media
Engagement with traditional and new media is necessary
in advance of and during outbreaks. Media play a critical role
in providing the public with real-time information about the
epidemic and response and also often report research find-
ings as well. Risk communication planning may include
table-top exercises to train reporters, editors, and publishers
about background rates of adverse obstetric and neonatal
events to mitigate sensationalist stories and avoid false attri-
bution of adverse events to vaccine use. This strategy was
successfully implemented in the campaign to vaccinate preg-
nant women during the 2009 H1N1 pandemic in the U.S. by
the National Vaccine Program Office.
14 C.B. Krubiner et al. / Vaccine xxx (xxxx) xxxCommunication plans should also anticipate the likelihood of
unintended exposures during pregnancy for any vaccine offered
to women of childbearing potential. Information should be pro-
vided on available evidence about potential risks of pregnancy
exposure. This will help pregnant women and their clinicians make
more informed decisions about clinical management options.
Communicating adverse events in pregnancy during outbreak
response
When pregnant women are included in a vaccine response to an
outbreak or epidemic, the communication plan for the vaccine
campaign should anticipate the prospect that pregnancy-related
adverse events will be suspected over the course of the campaign.
It is possible that an adverse event may be the result of vaccine
administration. However, as discussed in Recommendation 1, many
things can go wrong over the course of pregnancy into early
infancy, and some may be inappropriately attributed to the vac-Box 4. Pregnant women and influenza immunization
Pregnant women are considered a priority population for
influenza vaccination because they and their offspring are
at increased risk of complications from influenza, including
serious illness and death. Yet despite longstanding recom-
mendations for routine influenza vaccination in pregnancy,
immunization coverage remains low among pregnant
women. During the recent 2017–2018 influenza season, only
35.6% of pregnant women in the U.S. had received the flu
vaccine as of November 2017 – a significant drop from pre-
vious years where coverage was closer to 50% [55,75,76].
Although it is difficult to pinpoint the specific causes of lower
influenza vaccine uptake in 2017, one contributing factor may
have been a 2017 study highlighting a possible association
between miscarriage and influenza vaccines – and the media
response to the release of these findings [77–79]. ACOG and
the CDC promptly released statements about the limitations
of the study and reaffirmed the continued public health and
clinical importance of influenza vaccination in pregnancy,
but headlines about the possible ‘‘link” to miscarriage gave
rise to public concern [80–82]. This example highlights the
challenges of effectively communicating new findings that
signal potential vaccine-associated risks pregnancy, the cen-
tral role of the media as an information broker to the public,
and the limitations of current practices for messaging to the
public about recommended uptake of vaccines in pregnancy.
More work is needed to determine optimal modes and plat-
forms for professional organizations and the mainstream
media to responsibly and effectively communicate around
the risk of vaccine use in pregnancy to providers and preg-
nant women.
Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
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pregnancy-specific adverse events during an outbreak or epidemic
can lead to significant harms to pregnant women and their off-
spring, including women choosing to forego use of beneficial vac-
cines or unnecessarily seeking to terminate wanted pregnancies
[74] (see Box 4). Therefore, a critical best practice for communicat-
ing pregnancy-specific vaccine findings is to ensure that any
reports of adverse pregnancy or birth outcomes occurring during
the epidemic response are interpreted in light of the best available
information about baseline rates of adverse obstetric and neonatal
events, and should include an acknowledgement that a high per-
centage of adverse events in pregnancy have no known cause.
Additionally, any findings should be presented in conjunction with
the type, severity, and frequency of adverse obstetric and neonatal
events known to be caused by infection with the wild-type
pathogen.
Recommendation 4
Research efforts that aim to advance vaccine development by using
new technologies to study human immune system function and
response should include investigations specific to pregnant women
and their offspring.
 Directed to: clinical investigators; basic research scientists;
funders
There are currently a number of efforts underway to advance
our scientific understanding of the human immune system to
develop better, rationally designed vaccines and biologics. Because
pregnancy can alter the immune response and because both
maternal and fetal immune responses may change over the course
of gestation, it is important that these foundational studies exam-
ine the distinctive characteristics of maternal and fetal immune
systems. Understanding these differences could critically inform
the development and identification of new vaccines that are appro-
priate for use in pregnancy. For example, the Human Vaccines Pro-
ject has launched the Rules of Immunogenicity Program to
examine the underlying mechanisms required to generate appro-
priate and durable immune responses against infectious diseases
and cancer across the age spectrum and in diverse populations
[83]. This project presents an important opportunity to explore
how and why vaccines may work differently in pregnancy.
Additionally, more work is needed to understand the specific
dynamics of immune cell interactions at the maternal-fetal inter-
face. Notably, the NIH issued a funding announcement in June
2018 calling for proposals that identify and define immune mech-
anisms during normal pregnancy and explore the mechanisms of
immune responses triggered by infections or vaccination during
pregnancy [84]. We hope that this and other funding support will
stimulate further research in this space.
Recommendation 5
Mechanisms for incentivizing vaccine development for emerging
and re-emerging infections and mitigating existing disincentives
should include and address pregnancy-specific concerns of vaccine
developers.
 Directed to: policymakers; regulatory authorities; funders and
sponsors; vaccine developers; civil society organizations and
those who are positioned to influence vaccine research, adop-
tion, and delivery, including WHO, the World Economic Forum,
and CEPI
Vaccine research, development, and deployment take place
against the backdrop of the legal and financial interests of vaccinewomen & vaccines against emerging epidemic threats: Ethics guidance for
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C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx 15developers and manufacturers. Vaccine developers and manufac-
turers already face significant market challenges and uncertainties
in pursuing products targeting emerging and re-emerging patho-
gens [26]. These challenges can become even more complicated
when vaccine products are studied in and ultimately offered to
pregnant women – for whom there may be heightened concerns
of legal and financial liability [85].
Some mechanisms are currently in place in certain settings to
encourage development of beneficial biomedical products that
are unlikely to generate a profit, and other programs protect
against liability concerns when products are used in certain con-
texts, like public health emergencies, or by certain special popula-
tions, like children. These and new incentive programs need to be
intentionally inclusive of the needs and interests of pregnant
women.
Following the Ebola crisis of 2014, calls for a global vaccine
fund led to the creation of the CEPI to stimulate, facilitate, and
finance vaccine development against emerging pathogenic threats
– many of which would be unlikely to be pursued based on mar-
ket incentives alone [26,86]. Given CEPI’s central focus on de-
risking the vaccine development space for emerging infectious
diseases and their commitment to working with industry, regula-
tors, and other bodies to get vaccines developed, authorized, and
delivered to the people who need them, CEPI can play a pivotal
role in ensuring that pregnant women and their offspring fairly
benefit alongside other populations from these efforts and
investments.
Other mechanisms with proven international success in incen-
tivizing product development exist (see Box 5). Some may have
the potential to lower development costs, increase financial sus-
tainability, and cultivate early brand recognition and allegiance,
ultimately benefiting market share and encouraging product
development for those in need [87,88]. As these mechanisms are
explored and leveraged to promote the development of vaccines
against emerging pathogens, special attention should be offered
to products that will be suitable for use in pregnancy.Box 5. Incentive mechanisms to stimulate R&D
 Exemption from regulatory fees.
 Priority regulatory review and/or vouchers.
 Accelerated regulatory approval.
 Research and development tax credits.
 First-to-market or earlier market entry.
 Extended and/or longer duration of market exclusivity.
 Expedited patent review.
 Extended and/or longer active patent protection.
 Advance market commitments and other guaranteed
product purchase programs.
9 This is consistent with various CIOMS International Ethical Guidelines on
equitable distribution of benefits and harms of research, which state that: inclusion
and exclusion criteria should not be based on potentially discriminatory criteria
unless there is a sound ethical or scientific reason; for research in disease outbreaks,
adequate justification is given whenever particular populations are excluded; when
under-representation of groups results in or perpetuates health disparities, equity
may require special efforts to include members of those groups in research.At the same time, it will be critical to address disincentives con-
cerning the legal and financial risks of administering vaccines dur-
ing pregnancy. In the context of vaccine research studies, trial
insurance, indemnification, and compensation programs can miti-
gate those risks by anticipating and covering possible research-
related harms to the pregnant woman, fetus, and child subse-
quently born from that pregnancy. Some existing programs estab-
lished for the U.S. by the Public Readiness and Emergency
Preparedness Act protect individuals and entities from liability
claims when covered vaccines are administered during research
trials or through emergency response efforts [89,90]. This Act also
established the Countermeasures Injury Compensation Program,Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinwhich compensates any individuals – including pregnant women
and offspring who were in utero at the time of vaccine administra-
tion – who suffer specified, serious physical injuries from receiving
covered vaccines.
In recent years, there have been calls to establish a global vac-
cine injury compensation system to combat ‘‘the specter of vaccine
injury” – stating in particular the impact that compensation pro-
grams may have on vaccine development in the context of public
health emergencies [91,92]. Beyond the benefits associated with
mitigating liability concerns, scholars have noted that no-fault
compensation systems for adverse events attributable to vaccina-
tions offer further intrinsic and instrumental value: (1) they offer
compensation to those who suffered vaccine-associated injuries;
(2) they may address inequities inherent to vaccine-injury com-
pensation mechanisms that rely on litigation (particularly when
many affected have few resources to pursue legal suits) and (3)
the public health literature strongly suggests that no-fault com-
pensation systems increase public confidence in vaccination [93].
WHO, with support from partners at CEPI, World Economic Forum,
and Harvard Global Health Institute, is currently exploring the
establishment of a global no-fault compensation program that
would specifically cover serious adverse event resulting from the
use of non-licensed vaccines for emerging diseases with epidemic
potential. We encourage those working on this compensation
mechanism to explore ways this program can include features
specific to vaccine administration in pregnancy – such as allowing
for two claimants in the event that both the woman and her off-
spring suffer vaccine-associated adverse events.
Policymakers, regulatory authorities, sponsors, funders, civil
society organizations, and those who are positioned to influence
vaccine research and adoption should work together to identify
global and country-specific incentive mechanisms for development
and delivery of vaccines that pregnant women can use in the event
of an outbreak, while exploring additional ways to mitigate disin-
centives that could keep beneficial vaccines from reaching preg-
nant women.
Recommendation 6
To help ensure systematic and enduring change in the treatment of
pregnant women in global vaccine policy and practices, the World
Health Organization should convene a consultation of relevant
stakeholders and experts. The Consultation should identify specific
strategies to establish for pregnant women the presumption of
inclusion in both vaccine research and deployment, including
whether a dedicated, standing expert group is needed.
Standard approaches to determining when pregnant women can
be offered vaccines in the context of both research and delivery have
too often operated on a presumption of exclusion – that pregnant
women cannot or should not be eligible. This default mindset of
exclusion, often without scientific or ethical justification, has done
a great disservice to pregnant women and their offspring and must
be changed. It has resulted not only in unjustifiably excluding preg-
nant women from specific vaccine trials or specific vaccine deploy-
ment efforts, but also in obscuring the interests of pregnant
women from focal consideration in investments in vaccine research
and public health programming, more broadly.
Throughout9 this Guidance we make multiple recommendations
to help ensure that pregnant women and their offspring can fairlywomen & vaccines against emerging epidemic threats: Ethics guidance for
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Box 6. The presumptive inclusion of pregnant women
‘‘Presumption of inclusion” does not entail the automatic
or absolute inclusion of pregnant women in every vaccine
study or every vaccine campaign. Instead, a presumption of
inclusion changes the default position. It normalizes the posi-
tion that pregnant women are to be included in vaccine
deployment programs and vaccine research and develop-
ment. With inclusion of pregnant women as the default posi-
tion, the burden of proof, both scientific and ethical, falls on
those who want to argue for their exclusion. There will cer-
tainly be cases where the exclusion of pregnant women from
a particular vaccine trial or vaccine campaign will be justified,
but starting from a presumption of inclusion helps instantiate
and maintain a fundamental shift in the way pregnancy and
pregnant women are viewed in the field of vaccines. The pre-
sumption thus serves to reframe decisions about invest-
ments in vaccine research and development and about the
design of vaccine delivery efforts in ways that are profoundly
important from the standpoints of both public health and
equity (Also see Box 9).
10 Although the focus of this recommendation is on specific vaccine products an
maternal immunization, particularly in outbreak contexts, the consultation may be
useful platform to explore broader strategies to address the interests and unm
needs of pregnant women and their offspring as they pertain to the development an
delivery of a wider range of biomedical interventions.
16 C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx
Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pre
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j11 The JPEG could be modelled after the similarly structured Joint Technical Expert
Group (JTEG) on malaria vaccines, which was convened by the Immunization,
Vaccines, and Biologicals Department (IVBD) and the Global Malaria Program (GMP)
to provide advice on malaria vaccine development to both SAGE and the Malariabenefit from the protection that vaccines offer against emerging epi-
demic threats. These recommendations outline specific actions that
need to be taken, but institutional change at every level—globally,
regionally, and nationally—will be required to operationalize these
new approaches and move advisory and decision-making bodies
toward the new default of presumptive inclusion of pregnant
women (see Box 6 language). To seed this institutional change
and explore specific strategies for the systematic consideration of
pregnant women in international policies and practices governing
vaccine research and delivery, WHO should convene a multi-day,
global Consultation of relevant stakeholders.10
Consultation participants should include representatives from
regional regulatory networks and national regulatory authorities
(NRAs), such as: the African Vaccine Regulatory Forum (AVAREF);
the Pan American Pharmaceutical Regulation Harmonization Net-
work (PANDRH); the Developing Country Vaccine Regulators’ Net-
work (DCVRN); European Medicines Agency (EMA); U.S. Food and
Drug Administration (FDA); and other NRAs, as well as from
national ethics committees.
Experts in obstetrics and gynecology, maternal-fetal medicine,
pediatrics, and neonatology, especially those with experience in
infectious diseases, immunology, maternal immunization, and
research and public health ethics should be present (see Recom-
mendations 15 and 17), as well as stakeholder representatives from
industry, implementation partners in research and emergency
response, and funders.
The Consultation should provide a critical opportunity for rep-
resentatives across relevant WHO programs, initiatives, clusters,
teams, and advisory committees to discuss and determine the best
strategies to systematically integrate consideration of the interests
of pregnant women and their offspring throughout all WHO-
supported activities relevant to vaccine R&D, maternal immuniza-
tion, and emergency preparedness and response.
One such strategy that should be considered at the Consultation
is the establishment of a Joint Pregnancy Expert Group on Immu-
nization (JPEG). Structured as a standing body of interdisciplinary





.vaccinboth routine vaccination and vaccination in public health emergen-
cies. This interdisciplinary expert group could jointly report to exist-
ing WHO advisory groups, such as the Strategic Advisory Group of
Experts (SAGE) on Immunization and the proposed Strategic and
Technical Advisory Group (STAGE) on Maternal Health.11
We believe there are compelling reasons for establishing JPEG.
Creating a standing body at the World Health Organization
devoted to pregnant women and vaccines will bring global focal
attention to maternal immunization. The JPEG will send an unmis-
takable signal to the global health community that pregnant
women and their offspring, no less than other members of the pop-
ulation, should be permitted to benefit from the advances in health
that vaccines offer, and that there are responsible ways to ensure
that they do.
Moreover, making determinations about what is in the best
interests of pregnant women and their offspring during an emerg-
ing outbreak or epidemic often entails multiple and complex
assessments and the synthesis of rapidly emerging data frommany
settings. It is unrealistic and inefficient to expect every locality to
have the resources to be able to convene the expertise necessary
to assess vaccine use in pregnancy during an outbreak or epidemic.
However, absent an appropriate and timely process for making
these assessments, pregnant women and their offspring will con-
tinue to be seriously disadvantaged – with the default being their
exclusion from programs that deliver beneficial vaccines in emer-
gency responses.
The Consultation should also include consideration of ways to
support regional and national public health authorities who may
wish to establish similar groups of relevant and diverse experts
to advise their National Immunization Technical Advisory Groups
(NITAGs), Regional Immunization Technical Advisory Groups
(RITAGs), and emergency response teams. In addition, the Consul-
tation should address approaches to facilitate communication and
collaboration between national, regional, and global advisory
groups on pregnancy during outbreaks.Research & development of vaccines against emerging pathogenic
threats
Recommendation 7
Suitability for use in pregnancy should be a strong consideration in
development and investment decisions for vaccines against emerg-
ing pathogenic threats.
 Directed to: CEPI, U.S. Biomedical Advanced Research and
Development Authority (BARDA), and other funders and spon-
sors; WHO emergency response teams, R&D Blueprint teams
and TPP Working Groups; vaccine developers
The organizations shaping and investing in the vaccine pipeline
against emerging pathogenic threats have the opportunity to
ensure that, among the candidates that are prioritized for develop-
ment, there are at least some that use platforms and adjuvants that
are most likely to make them suitable for use during pregnancy.
Early investment in options that are most likely to be acceptablePolicy Advisory Committee (MPAC). For more on the JTEG, see: Kaslow DC, Biernaux S.
RTS, S: toward a first landmark on the Malaria Vaccine Technology Roadmap. Vaccine.
2015 Dec 22;33(52):7425–32 and WHO Initiative for vaccine research/global malaria
programme joint technical expert group (JTEG) on malaria vaccines entering pivotal phase
3 trials & beyond (April 2009-February 2016). Terms of References. Accessed 8 Aug
2018. Available from: http://www.who.int/immunization/research/committees/jteg/
en/
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13 Live-attenuated vaccines have usually been contraindicated in pregnancy, though
not always, as evidenced by Yellow Fever vaccine, which is recommended for use in
pregnancy where Yellow Fever exposure is possible. Contraindications have revieved
special weight where the vaccine is derived from a replicating virus that has known
associations with congenital malformations (e.g., Rubella). Although no observed
cases of vaccine-associated congenital rubella syndrome have been documented, the
vaccine remains contraindicated in pregnancy, though recent recommendations
emphasize that inadvertent exposure should not prompt discussions of pregnancy
termination (e.g., CDC Guidelines for Vaccinating Pregnant Women) Further, there is
C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx 17during pregnancy can pave the way for pregnant women and their
offspring to realize benefits from vaccine candidates that ultimately
prove successful – and help ensure that they, like other population
groups, will be protected from emerging infectious diseases.
For pathogens that pose significantly higher threats in preg-
nancy – of fetal harm, maternal harm, or as is often the case, both
– funding calls should designate greater investment priority to
candidates likely to be suitable for use during pregnancy. When
pregnant women or their offspring are at higher risk of harm from
the pathogen, it would be particularly unjust for their needs not to
be included in vaccine development priorities. Moreover, because
the business case for developing vaccines for outbreak diseases is
often weak, much of the investment in vaccine R&D comes from
public funding sources. The large role for public financing under-
scores the justice claims of pregnant women to have their needs
fairly included in societal investments in vaccine development.
Funding agencies also have the responsibility to help ensure
that pregnant women will not be left behind as vaccine technology
advances. Novel vaccine technologies, such as nucleic acid and
viral vector platforms, represent an increasingly important part
of the vaccine R&D pipeline for emerging and re-emerging patho-
gens. However, little is known about their safety in pregnancy,
although there is optimism about their use in pregnant women
[94].12 Funders who are supporting the development of vaccines
for emerging pathogens that rely on novel technologies should
require and fund research activities to help fill this gap, including
timely developmental toxicology studies for vaccine candidates
demonstrating promise in phase 1 studies, studies of immune
response in pregnancy, and the inclusion of pregnant women in
pre- and post-market research when ethically and legally permissi-
ble (see Recommendations 9, 10, and 11).
As noted earlier, there has been a dramatic shift toward proac-
tive investment in the development of vaccines against emerging
pathogens since the 2014 Ebola crisis, as part of larger efforts to
strengthen epidemic preparedness. Emblematic of this shift is the
launch of CEPI, a partnership between public, private, philan-
thropic, and civil society organizations that is supporting the
development of several promising vaccine candidates against pri-
ority pathogens ahead of outbreaks. There are also a range of
WHO activities designed to better coordinate global research
efforts that should be leveraged to appropriately address the inter-
ests of pregnant women and their offspring in vaccine R&D. These
include the WHO R&D Blueprint and Roadmaps, as well as Target
Product Profiles (TPPs) and Preferred Product Characteristics
(PPCs) for vaccines being developed against specific pathogens.
Collectively, these documents highlight the broad priorities for
preparedness and response and signal the target populations and
product characteristics that academic and commercial researchers
should pursue when developing interventions. For pathogens that
pose significantly higher threats in pregnancy, pregnant women
should be included among the target populations, and one or more
vaccines that are suitable for use in pregnancy should be included
among the types of vaccines targeted for development.
It will ultimately fall to researchers and funders to prioritize
developing vaccine candidates with acceptable characteristics for
use in pregnancy. When reviewing proposals, funding agencies
such as CEPI, BARDA, NIH, the European Commission, the Interna-
tional Vaccine Initiative, and others should strongly consider the
likely acceptability for use during pregnancy of each vaccine candi-
date, alongside the other review criteria, and include some candi-
dates that are likely to be suitable for use during pregnancy as12 ‘‘. . .the ideal vaccine will be based on a non-replicating platform that is safe for
use during pregnancy. These platforms include inactivated whole virus, subunit, or
mRNA-based or DNA-based vaccines that express selected viral proteins.” In: Poland
et al, 2018.
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preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinpart of the overall portfolio of funded proposals. It is worth empha-
sizing that many products developed with the intent to be safe and
effective in pregnancy are likely to be safe and effective in other
affected populations and can be widely deployed.
Recommendation 8
When pathogens pose a risk of severe harm to pregnant women or
their offspring and the most promising vaccine candidates are
likely to be contraindicated for routine use in pregnancy, invest-
ments should be made in alternative vaccine candidates that could
be more readily used in pregnancy.
 Directed to: CEPI, BARDA, and other funders and sponsors; vac-
cine developers
It is possible that the vaccine candidates that move most rapidly
through the R&D pipeline turn out to be problematic for use in
pregnancy, even when a concerted effort in investment and fund-
ing decisions has been made upstream to keep this from happen-
ing. For example, as a candidate advances through various stages
of clinical development, an otherwise promising vaccine may pro-
duce high fever in some research participants, raising concerns
about its use in pregnancy because of documented associations
between high fever in pregnancy and congenital malformations
[95–97]. Unless other vaccines with more favorable profiles for
use in pregnancy are then prioritized, it is possible that pregnant
women and their offspring will end up without any vaccine protec-
tion against the emerging pathogenic threat.
This prospect is problematic from both a public health and
ethics perspective, and is particularly dire when the target patho-
gen has more severe consequences in pregnancy. When pregnant
women and their offspring suffer more than other population
groups from the emerging infectious disease threat, justice calls
for the vaccine enterprise to make every reasonable effort to bring
to market a product pregnant women can safely and effectively
use. Consider, for example, the case of Zika virus (ZIKV), where
the most devastating effects of the virus are caused by infection
in pregnancy. If the only promising candidate to advance to phase
3 trials were a live-attenuated ZIKV vaccine, pregnant women
might be left behind, even though their offspring are most at risk
for harm from ZIKV. In this case, because there is a theoretical risk
of the live-attenuated vaccine causing the very condition it seeks to
avert,13 investing in the development of candidates that do not
entail this risk is critical to ensuring that pregnant women have an
available option to safeguard their fetuses and themselves in the
event of future ZIKV outbreaks.
ZIKV is not the only emerging or re-emerging pathogen where
pregnant women and their offspring face higher risks than other
affected populations. Consider another WHO priority pathogen,
Lassa Fever virus, where a vaccine option for pregnant women is
critically important. Documented mortality rates for hospitalized
patients with Lassa Fever have typically ranged between 15 andwidespread reticence among providers generally to use live vaccines, whether or not
the wild-type virus is associated with congenital defects (see Box 12). In the case of
ZIKV, there would have to be significant efforts to establish the safety profile of a live-
attenuated ZIKV vaccine in pregnancy, and many experts agree it is unlikely that
adequate evidence would be gathered that would lead to a recommendation for use in
pregnancy.
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Box 7. Novel yellow fever vaccines and immunogenicity
studies absent an outbreak
Consider the case of a new Yellow Fever (YF) vaccine can-
didate that employs a platform that is not replication-compe-
tent – compared with the current live-attenuated YF vaccine
that has been in use since the 1930s. The current vaccine is
quite effective at inducing long-lasting immunity. However,
there has been recent interest in pursuing new YF vaccines
because of concerns about rare but serious adverse events
in the general population associated with the current pro-
duct, as well as additional precautions regarding the use of
the live-attenuated vaccine in young infants, the elderly,
immuno-compromised people, and pregnant and lactating
women [110]. New YF vaccine candidates using inactivated
virus and nucleic acid platforms may have better safety pro-
files [108,111–114]; moreover, recent supply issues under-
score the potential advantage of novel vaccines that can be
rapidly manufactured to better meet demand, particularly
during public health emergencies and pandemics [115–118].
If a new YF vaccine candidate stimulated sufficient protec-
tive immunity in healthy, non-pregnant adults, and evidence
suggested that the safety profile of the new candidate for
pregnant women was better than the current live-attenuated
vaccine, it would be important to conduct further studies
assessing the immune response of this new vaccine among
pregnant women. As some studies suggest that immune
responses in pregnancy to the current YF vaccine may be
impaired, it would be critical to determine whether the new
vaccine would be sufficiently protective in pregnant women
compared with their non-pregnant counterparts [108,119].
Because there are established correlates of protection for
YF vaccines, immunological bridging studies in pregnant
women could be conducted. Also, for pregnant women living
in communities where YF is a recurrent threat, the benefits of
receiving the experimental vaccine, which include not need-
ing to be exposed to the current vaccine, would likely out-
weigh the risks. This is just one hypothetical example to
illustrate a case in which it would be scientifically andmorally
important and appropriate to assess immune response in
pregnancy between or ahead of potential exposures.
18 C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx20% (with some instances of mortality over 50%), but for women in
their third trimester of pregnancy, mortality rates climb to 80–90%
[98–100]. Not only is the risk of death significantly higher in preg-
nancy, but ribavirin, the primary treatment for Lassa Fever, is con-
traindicated for use in pregnancy due to suspected associations
with birth defects [101].14 Many of the vaccine candidates under
development for Lassa Fever employ novel vaccine platforms or
replication-competent viral vectors, including two platforms that
have recently received CEPI funding [102]. If early safety data do
not support evaluation of these vaccines in pregnant women, or their
use in pregnant women during an outbreak, then additional vaccine
candidates should be developed.
Recommendation 9
Non-clinical studies that are a prerequisite for clinical trials in
pregnant women, such as developmental toxicology studies,
should be initiated early in the clinical development of promising
vaccine candidates, before efficacy trials are planned.
 Directed to: CEPI, BARDA, and other funders and sponsors; vac-
cine developers; national regulatory authorities
Under the new preparedness frameworks noted above, organi-
zations like CEPI have committed to supporting ‘‘just-in-case” vac-
cine development, from pre-clinical stages through phase 2 clinical
studies, so that promising candidates can be quickly evaluated in
large-scale trials during outbreaks [103]. As a matter of equity,
pregnant women should be able to participate in these studies
when appropriate vaccine candidates are identified and the likely
benefits of participation outweigh the risks (see Recommendation
11). However, current regulatory guidance requires that certain
non-clinical studies, such as developmental toxicology studies in
animals, must be completed prior to including pregnant women
in clinical trials [104–107].
For this reason, required non-clinical studies for evaluation in
pregnant women should be conducted while promising vaccines
move through phase 1 and 2 clinical trials, so that these vaccines
could be offered without delay to pregnant women during an out-
break, whether in research or deployment. While not all vaccine
candidates will successfully advance through clinical trials, plans
should be made at the outset, and funding secured, to allow timely
non-clinical evaluations for appropriate vaccine candidates.
Recommendation 10
Studies to assess immune responses to vaccines in pregnancy
should be conducted before or between outbreaks whenever scien-
tifically possible and ethically and legally acceptable.
 Directed to: CEPI, BARDA, and other funders and sponsors; vac-
cine developers; clinical investigators
Although much of the work to evaluate vaccines in pregnancy
will be done during outbreaks and epidemics (see Recommendation
11), there will be some cases in which it will be both beneficial and
feasible to generate immunogenicity data in pregnancy before or
between outbreaks. Because immune system functioning is altered
in pregnancy, it is possible that a vaccine will be less immunogenic
or induce atypical immune responses in pregnant women, with
potential implications for its effectiveness as well as the dosing
and frequency required in pregnancy to generate sufficient protec-14 The contraindication for ribavirin in pregnancy is currently based on an animal
model that found signals of teratogenicity. There are pregnancy registries collecting
data on possible effects of in-utero exposures to ribavirin, and while they have yet to
find signals of associated birth defects in humans, the sample size is still to small to be
conclusive (Sinclair SM, et al, 2017).
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preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccintion [108,109]. Immunogenicity studies would be particularly
valuable if a correlate of protection for the vaccine has already
been established. These studies would also provide opportunities
to gather additional safety data for these vaccines in pregnancy.
In the absence of an outbreak or epidemic, it may be difficult to
demonstrate that studies to assess immune response in pregnant
women have a favorable risk-benefit profile. However, there may
be instances in which the future occurrence of an outbreak among
a particular population is likely enough to conclude that the poten-
tial benefits of being protected would outweigh the risks
associated with a particular candidate vaccine. The example in
Box 7 provides an illustration of such an instance.Recommendation 11
Clinical development plans for investigational vaccines against
emerging and re-emerging pathogens should include studies
designed to evaluate vaccines in pregnancy. Pregnant women
should have opportunities to enroll in vaccine studies conducted
during outbreaks and epidemics whenever the prospect of benefit
outweighs the risks to pregnant women, their offspring, or both.
 Directed to: CEPI, BARDA, and other funders and sponsors; vac-
cine developers; clinical investigators and trial implementation
partners; research ethics committees; national regulatory
authoritieswomen & vaccines against emerging epidemic threats: Ethics guidance for
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Box 9. Fair access to trialswith theprospect of direct benefit
C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx 19This recommendation rests on two claims of justice about the
importance of treating pregnant women and their offspring fairly
in the conduct of research on vaccines for emerging and
re-emerging infections. The first of these justice claims pertains
to pregnant women who may be affected by outbreaks and epi-
demics, as a class. The second concerns individual pregnant
women who live in areas where trials are being conducted
amidst outbreaks.
Pregnant women as a class
As we have noted throughout, the distinct physiology of preg-
nancy, together with concerns about fetal effects, limits the extent
to which evidence from non-pregnant adults can establish an ade-
quate evidence base for vaccine use during pregnancy. Because of
reasonable constraints on sample size and length of follow-up, it
is likely not possible to generate the same level of evidence about
efficacy and safety for pregnant women and their offspring as for
the general population. That said, as a matter of equity, as well
as public health, the evidence base for pregnant women should
be as good as possible and generated as contemporaneously as
possible as the evidence for the general population. This
requires development of an evidence base that includes data
obtained directly from pregnant women.
For many pathogenic threats, including those that emerge only
intermittently, outbreaks may be the only time in which it is pos-
sible to generate critical pieces of evidence on investigational vac-
cines in pregnancy. Alternative strategies to generate evidence on
vaccines during non-outbreak periods, such as phase 1–2 studies
or human challenge trials, have ethical and regulatory constraints
limiting the involvement of pregnant women, particularly where
they offer no prospect for direct benefit.
At minimum, sufficient numbers of pregnant women should
be recruited in vaccine efficacy trials during outbreaks to allow
an assessment of immunogenicity and to gather as much evi-
dence as possible about safety. Clinical development plans and
study protocols may adopt a range of approaches for collecting
data from pregnant women, including the conduct of parallel
or companion studies to the main efficacy trial or through a
sub-study of the main trial.
While data collected frompregnantwomenmay not be analyzed
withdata fromthemain trial, investigators should integrate analysis
of data collected from pregnant womenwith data from participants
in the main efficacy trial who become pregnant (see Recommenda-
tion 12), including information regarding relevant differences in
week of gestation at time(s) of administration(s) (see Box 8).Box 8. Randomization of pregnant women in vaccine
studies
There may be cases in which prospectively enrolled preg-
nant women should not be randomized, even if randomiza-
tion is acceptable for the main study population. For
example, when the probability and severity of harms asso-
ciated with infection are significantly greater in pregnancy
compared with other affected populations, with few available
alternatives, and the vaccine shows promise for immunologi-
cal protection, it may be unethical to assign pregnant partici-
pants to anything but the investigational vaccine. Another
reason why it may be appropriate to assign all pregnant par-
ticipants only to the investigational vaccines is that projected
sample sizes for pregnant women may not be large enough
to detect statistically significant differences between a control
group and an intervention group.
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There is a second, independent reason motivated by justice as to
why pregnant women should have opportunities to participate in
efficacy studies of vaccines conducted in outbreak settings. As
the moral equals of others, pregnant women should have fair
access to the prospect of direct benefit that may come from receiv-
ing an experimental vaccine [8].
The principle of fair access to research participation is a key and
independent pillar of research ethics. When research offers partic-
ipants the prospect of direct benefit, this principle requires that
those who could benefit from inclusion and otherwise meet gen-
eral criteria of scientific relevance and regulatory protection be
afforded the opportunity to enroll. This applies to pregnant women
no less than to other potential research subjects. Indeed, for preg-
nant women, the benefits of research participation may be espe-
cially high. Pregnancy can make a woman more susceptible to
infection and exacerbate the risks associated with some patho-
gens; and benefits may accrue to two entities, the woman and
her future child. Like all potential research participants, pregnant
women may differ in their interest in participating in a vaccine
study. That said, they should be afforded a fair opportunity to pro-
tect themselves and their offspring from the circulating pathogen
through research participation that is comparable to the chance
available to members of other affected groups.
When the clinical development plan does not include studies
with pregnant women during outbreaks, despite a prospect of
net benefit from their participation, a double injustice results.
The claim of pregnant women to an evidence base appropriate to
their needs is denied, and the claim of individual pregnant women
to fair access to participate in studies of the investigational vaccine
is also denied. The best outcome in this circumstance is for the
clinical development plan to be amended and resources secured
to initiate studies with pregnant women as quickly as possible.
Those responsible for clinical development plans that offer no
opportunity for pregnant women to enroll in vaccine efficacy
studies conducted during outbreaks must provide sufficient
and scientifically valid justification for excluding pregnant
women from this research (see Box 9). When pathogenic threats
are particularly serious, or when pregnant women and their off-
spring face the most severe harms of infection, it may be very dif-
ficult to ethically justify their exclusion from vaccine studies.Fair access to research is not equivalent to automatic
access. Instead, it means that restricting eligibility based on a
given condition or demographic profile must be based on
acceptable justification for exclusion. Reasons that are not
considered acceptable bases for exclusion from research
involving prospect of direct benefit include logistical costs; lia-
bility issues; that somepeoplewould bemore costly to recruit,
retain, or responsibly care for or oversee; or past practices of
exclusion. Reasons that are considered acceptable include an
individual not meeting criteria of scientific relevance or not
meeting standards of acceptable research-related risk. In
between are reasons of scientific complexity or risks to
ongoing research. Whether or not these reasons justify exclu-
sion in a given instance will depend on the importance of the
research, the potential for adjusting the research design in
ways that will allow inclusion, and the degree of prospective
benefit of participation to the individuals who would be
excluded. In general, the stronger the potential net benefit of
participation and, more specifically, the stronger the benefit
to thosewhowouldbe excluded relative to other potential par-
ticipants, the higher the burden of justification for exclusion.
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research
For both sets of reasons outlined above, it is critical that vaccine
research conducted during outbreaks include appropriate plans for
research with pregnant women whenever the research meets eth-
ical standards for permissible enrollment of this population. These
standards generally consider pregnant women eligible for enroll-
ment in research involving medical interventions if the risk to
the fetus is minimal or, as is more likely here, when there is a rea-
sonable judgment that the prospective benefits of enrollment out-
weigh the risks, and that research participation has the prospect of
being at least as net beneficial as alternatives to participation.
These ethical standards are reflected in regulations governing
research with human subjects (see Appendix A). Should the jurisdic-
tion in which research is to be conducted have regulations that
would not permit research with pregnant women even when the
likely benefits outweigh the risks, sponsors and investigators will
have to abide by these requirements. However, they should make
efforts to persuade regulators to change the regulations or to make
an exception in view of the public health and equity interests that
are at stake.Table A
Considerations for assessing risks & benefits of including pregnant women in vaccine rese
Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinFor vaccine research, determining whether the prospect of ben-
efit outweighs the risks for pregnant women and their offspring
will depend on a series of factors (see Table A), including character-
istics of the vaccine candidate as well as the epidemiological con-
text in which studies are conducted. In some cases, it will be clear
that the prospect of benefit far outweighs the risks of receiving the
investigational vaccine: for instance, when there is a severe threat
in pregnancy, high rate of transmission in the study area, a vaccine
candidate that has been developed using a platform generally con-
sidered safe in pregnancy, no safety signals from earlier studies,
and good indicators of potential efficacy. In other cases, sponsors,
investigators, and research ethics committees will have to carefully
consider multiple factors to determine whether the risk-benefit
profile is favorable for prospective enrollment.
A number of resources have been developed in recent years to
provide guidance on protocol design and safety assessments for
research on vaccines anticipated to be used in pregnancy, including
the guidance developed by the Global Alignment of Immunization
safety Assessment in pregnancy (GAIA) and The Brighton Collabo-
ration (see a list of published resources in Appendix C) [120–122].
Though not restricted to the special case of public health emergen-arch & delivery.
(continued on next page)
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C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx 21cies, these resources specify data that ideally would be acquired
prior to enrolling pregnant women in vaccine trials, provide stan-
dard definitions for assessment of key obstetric and neonatal
health outcomes and of adverse events in pregnancy, and guideli-
nes for protocol development and sequencing of developmental
toxicology studies to allow timely enrollment of pregnant women.Recommendation 12
Vaccine studies that include women of childbearing potential
should have plans to systematically collect data on immunogenicity
and pregnancy-specific indicators of safety from participants who
are unknowingly pregnant at the time of exposure or become preg-
nant within a relevant window following vaccine administration.
 Directed to: CEPI, BARDA, and other funders and sponsors; vac-
cine developers; clinical investigators and trial implementation
partners; research ethics committees; national regulatory
authorities
In trials enrolling women of childbearing potential, including
vaccine trials conducted in outbreak contexts, it is predictable
and should be expected that some women not known to be preg-
nant at the time of enrollment will nevertheless be so, or willPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinbecome pregnant later in the course of the trial. This will occur
even when pregnancy tests are required and contraception is
advised or provided. Those implementing vaccine trials, whether
trials are directed against pathogens that are endemic or epidemic,
should develop and include a well-designed, prospective plan to
systematically capture data on maternal, fetal, and infant out-
comes whenever these unintended exposures occur. These data
should be collected using standardized methods and case defini-
tions, such as those proposed by GAIA [121,122].
Historically, data from inadvertent exposures during pregnancy
have been a key source of information regarding the safety profile of
vaccines in pregnancy [123]. These data have been used to inform
both clinical and public health practice. Of note, data collected from
trial participants who are not known to be pregnant at the time of
administration can also provide evidence about the effects of vac-
cine exposure earlier in pregnancy thanwould be available through
trials prospectively enrolling pregnant women. This would include
data during the time of organogenesis, which could be important to
address safety concerns around teratogenicity.
However, data from inadvertent exposures during pregnancy
must be cautiously interpreted, particularly when events occur in
early pregnancy. Since up to a third of early pregnancies end in
miscarriage, the risk that a ‘natural’ loss will be misattributed towomen & vaccines against emerging epidemic threats: Ethics guidance for
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Box 10. Generating evidence and interrogating safety signals
when trial participants become pregnant
A recent informative example includes analyses of the risk
of miscarriage among pregnancies conceived within 90 days
following administration of an ASO4-adjuvanted bivalent
human papillomavirus (HPV) vaccine. In 2010, the Data Safety
Monitoring Board for a trial enrolling women and girls of
reproductive potential noticed an imbalance in incidence of
miscarriage among participants who became pregnant in
the HPV arm compared with the control arm – prompting
further analysis of the data [125]. The investigators were able
to conclude that there was no associated increase in miscar-
riage or other adverse pregnancy or birth outcomes among
women who conceived more than 90 days after vaccination.
However, this analysis was unable to ‘‘completely rule out
the possibility of an increased risk among pregnancies con-
ceived within three months of vaccination.” [125] Subsequent
analysis of a larger dataset found no evidence of increased
risk of miscarriage for pregnancies conceived less than 90
days after vaccination [126]. This example illustrates two
key concepts: first, that initial trials may be used for signal
detection that can guide future studies; second, that baseline
rates or other appropriate comparators of adverse pregnancy
outcomes are important, as they were used to assess
whether rates of miscarriage among those receiving the
HPV vaccine were meaningfully different than rates in their
unvaccinated counterparts.
15 CIOMS guidance recommends that all trials enrolling women of childbearing
potential should inform the women participating of potential risks to the fetus if they
become pregnant and guarantee access to effective contraceptive options. (Guideline
18). Nevertheless, even in ideal circumstances, many women become pregnant while
enrolled in trials. CIOMS guidance also endorses the the position that ‘‘When there is
no evidence on the basis of which a potential harm to the fetus can be assumed, women
who become pregnant should not automatically be removed from the study, but must be
offered the option to continue or end their participation.” We go a step further to state
that any evidence of risk from additional vaccine doses would have to outweigh
prospect of benefit to deny these women opportunities to complete the vaccine
schedule in the study.
22 C.B. Krubiner et al. / Vaccine xxx (xxxx) xxxvaccination is a serious concern and should be avoided [124]. Any
signals of adverse events, including early pregnancy loss, should be
interpreted in the context of the best available data on background
rates of pregnancy-specific outcomes (see Recommendations 1 and
3).
Another challenge to interpreting adverse events among preg-
nant women in the context of vaccine trials conducted in out-
break settings is that the pathogen itself or other agents may
be contributing to adverse outcomes, and not the vaccine.
Although it may be difficult in an outbreak situation to collect
all the needed data, to the extent possible, the study should
screen for other possible causes of maternal, fetal, infant, and
child harms.
A well-designed plan should also test for relevant correlates of
immunity (if known) to determine level of protection from vaccine
administration. This last point will have particular relevance to
both the individuals exposed in a trial who need to know if they
are protected against the pathogen, and to women who may be
exposed during pregnancy in future vaccination campaigns.
Wherever possible, systematic observational studies that are
designed to capture data from inadvertent exposures to vaccine
during pregnancy should also include longitudinal evaluation of
immunogenicity to assess: the durability of protective immunity
for future pregnancies; passive antibody transfer and active
immune response among neonates exposed in utero (cord blood
at minimum); longer-term follow up among children exposed in
utero to replication-competent candidates to assess for the
potential of vaccine-associated congenital harms; and viremia
and viral shedding among women exposed to the vaccine. For
live vaccines and replication-competent vectors, evaluations of
pregnancy-specific safety outcomes and immunity should also
include women who become pregnant shortly after administra-
tion. These data may help to inform clinical and personal
decision-making when pregnancy occurs shortly after immuniza-
tion (see Box 10).Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinRecommendation 13
Women participating in vaccine trials who become aware of a
pregnancy during the trial should be guaranteed the opportunity,
through a robust re-consent process, to remain in the trial and
complete the vaccine schedule when the prospect of direct benefit
from completing the schedule can reasonably be judged to out-
weigh the incremental risks of receiving subsequent doses.
 Directed to: clinical investigators and trial implementation
partners; vaccine developers; research ethics committees;
national regulatory authorities
All those implementing vaccine trials that enroll women of
childbearing potential, including vaccine trials conducted in out-
break contexts, should have a plan to respond when a participant
becomes pregnant [10].15 This plan should include asking women
who become pregnant whether they would be willing to participate
in a long-term follow-up study, as described in Recommendation 12.
The plan should also address whether a woman who becomes preg-
nant before completing a vaccine schedule should be permitted to
receive additional doses.
For vaccine trials in which pregnant women are permitted to
prospectively enroll, participants who become pregnant after
enrollment should be permitted to continue to receive vaccine
doses if they choose to do so after a robust re-consent process.
The re-consent process should include any pregnancy-specific
issues, including those not explicitly or comprehensively
addressed in the consent process prior to pregnancy.
In trials in which pregnant women are excluded from
prospective enrollment, the determination about continued
dosing will be complex, but should not default to presumptive
discontinuation. Instead, the decision should be based on an
assessment of the best available evidence on the potential bene-
fits and harms of the vaccine for pregnant women and their off-
spring. The decision should also be based on the particular
circumstances of the pregnant participant and the maternal-
fetal risks and benefits specific to her situation, including possi-
ble risks associated with receiving an incomplete vaccination
series and the risks already incurred from the first vaccination
(Table A). Here again, a robust re-consent process will be essen-
tial to allowing pregnant women to determine whether they
want to receive additional doses.
Regardless of whether they choose or are permitted to continue
completion of the vaccine schedule, women who become aware of
a pregnancy while participating in a vaccine trial should be pro-
vided all study-related benefits and ancillary care to which they
would otherwise be entitled if they continue to come for non-
interventional follow-up. These study-related benefits are owed
not only because these women will likely continue on as partici-
pants in a parallel observational study to gather important
follow-up data, but also as a matter of reciprocity for the contribu-
tion they have already made by volunteering in the original vac-
cine study.women & vaccines against emerging epidemic threats: Ethics guidance for
e.2019.01.011
Box 11. Examples of paternal consent requirements
In Saudi Arabia, Article 26 of the Implementing Regula-
tions of the Law of Ethics of Research on Living Creatures
necessitates that researchers seek informed consent from
both the pregnant woman ‘‘and her husband,” making no
exception in cases of benefit to the pregnant woman [130].
Similarly, the Ugandan National Guidelines for Research
involving Humans as Research Participants requires that
informed consent be obtained from both the mother and
father unless ‘‘the purpose of the research is primarily tomeet
the health needs of the mother.” [131] In this case, paternal
consent is required if the purpose of the research is to benefit
both the fetus and themother, which is likely to be the case for
many vaccine studies. Similar paternal consent requirements
exist in several Latin American countries [132].
C.B. Krubiner et al. / Vaccine xxx (xxxx) xxx 23Recommendation 14
When a pregnant woman of legal standing to consent is judged eli-
gible to enroll or continue in a vaccine trial, her voluntary and
informed consent should be sufficient to authorize her
participation.
 Directed to: clinical investigators and trial implementation
partners; research ethics committees; national authorities in
charge of governance and oversight of human subjects research
As a matter of respect, and as a key aspect of ensuring fair
access to investigational vaccines for which the prospect of benefit
outweighs the risks, the consent of pregnant women who are
judged eligible to participate in or continue receiving doses in a
vaccine trial should be sufficient for participation. Pregnant
women are the moral equals of other self-governing adults. CIOMS,
PAHO, and Subpart B of the U.S. Code of Federal Regulations (45
CFR Part 46) are clear that pregnancy is no exception to the princi-
ple that competent adults are the locus of consent for trials that
offer the potential to benefit them [9,10,127]. Further, requiring
the consent of additional actors can present a material barrier to
the benefits research may offer to the offspring – a core rationale
in pediatric research for not requiring consent to be procured from
both parents when the research offers the child the prospect of
direct benefit.
Researchers should support pregnant women who wish to
involve partners, family members, and other personal supports in
the decision to join or remain in vaccine trials. It is important for
community trust that fathers16 and other partners are given the
opportunity to engage with and learn about the trial, and there
may be cultural contexts in which accommodations should be made
to facilitate a woman’s ability to engage her spouse or family when
she believes it would be helpful or important before agreeing to par-
ticipate in a research study [127]. That said, at the end of the day, for
any research involving the prospect of direct benefit, to either the
pregnant woman or her offspring, her consent, and hers alone,
should be sufficient.
Oversight entities, such as research ethics committees, should
be aware of any added consent requirements that might be man-
dated by the specific regulations governing proposed protocols. It
is worth noting, for instance, that Subpart B of U.S. regulations
45 CFR 46 governing research with human subjects currently
requires the father’s additional consent for one unusual scenario,
namely, research that holds out the prospect of direct benefit solely
to the fetus, but offers no prospect of clinical benefit to the woman
(with exceptions for the father’s unavailability, incompetence, or
temporary incapacity, or in cases of pregnancy resulting from rape
or incest). This requirement has been strongly criticized as prob-
lematic, often unworkable in practice, and out of step with parental
consent for pediatric research offering the prospect of direct bene-
fit, which requires only one parent to consent [128,129]. Still,
researchers will need to be compliant with governing regulations.
Fortunately, Subpart B should only rarely be at issue in vaccine
studies conducted in outbreak contexts because the investigational
vaccine is very likely to offer pregnant women themselves the pro-
spect of direct medical benefit. Even if the future child is likely to
benefit more than the pregnant woman, the fact that the woman16 We use the term ‘‘father” in this instance to refer to the male who would be the
biological father of any child resulting from the pregnancy. We recognize that the
contribution of genetic material resulting in a pregnancy does not alone constitute
‘‘fatherhood” – in general and especially prior to the birth of a child. Nor does it imply
that the individual involved in conception has an active relationship or partnership
with the pregnant woman who would give her consent. We use the term, ‘‘father,”
however, because it is easiest to understand in the context of seeking paternal
involvement in any consent processes and because it reflects the langauge included in
various regulations governing human subjects research.
Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinstands to benefit on her own ensures that only the pregnant
woman’s consent is needed under Subpart B.
In some regulatory contexts, there may be explicit require-
ments that the father’s consent be obtained for most or all research
involving pregnant women, even when there is a prospect of direct
benefit to the woman (see Box 11). Although the pregnant woman’s
consent should be sufficient to authorize participation, researchers
must be aware of the local laws in the setting in which they are
conducting a trial and comply with any legal paternal consent
requirements. However, they should support the work of gender
and health advocates and others to change the requirement.
As the age of consent for research participation is jurisdiction-
specific, researchers should consult local legal experts to determine
the specific age for sole authorization for their study locations.Recommendation 15
Experts in maternal and perinatal health, pediatrics, and research
ethics should be involved in decisions about funding; trial design;
research ethics oversight; and the generation, analysis, and evalu-
ation of evidence on vaccine use in pregnancy.
 Directed to: funders and sponsors; vaccine developers; clinical
investigators; research ethics committees; national health
authorities in charge of research governance and regulations;
data safety monitoring boards
Pregnant women deserve that decisions and evaluations affect-
ing them will be made in careful, thoughtful, and evidence-based
ways, involving the most informed experts possible. In Recommen-
dation 6, we put forward for consideration that the WHO create a
body of interdisciplinary experts to inform decisions about vaccine
use in pregnancy in the public health response context. Here we
make a similar recommendation to have appropriate expertise
informing various activities related to vaccine R&D [40].17 In this
instance, experts will need to be integrated into the multiple bodies
that deliberate on funding, trial design, research ethics oversight,
and data analysis.
The involvement of experts in obstetrics and gynecology,
maternal-fetal medicine, pediatrics, neonatology, and research
ethics in setting priorities for funding will help ensure that preg-
nant women and their offspring will not be overlooked as vaccine17 This recommendation is consistent with a call from U.S. CDC and HHS officials to
establish ‘‘a network of experts in obstetrics and pediatrics research” that could be
called upon in the event of a public health emergency in which considerations of
pregnancy are central to inform development, evaluation, implementation, and
analysis of trials. See: Faherty LJ, Rasmussen SA, Lurie N. AJOG. 2017.
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of these experts in the design of clinical trials and other data-
gathering activities will help ensure that decisions about the inclu-
sion or continued participation of pregnant women are based on
the most informed understanding of the risk and prospect for ben-
efit to pregnant women and their offspring of participation and
non-participation. Of particular value will be experts in maternal
and child health and in research ethics who have a demonstrated
commitment to advancing the evidence base in pregnancy and
who have experience with infectious diseases, immunology, and
maternal immunization.
Including this diversity of relevant expertise will also
strengthen the validity and utility of these evidence-generating
activities by helping to ensure the identification of appropriate
endpoints and the interpretation of findings in terms of parameters
of normalcy for pregnant women, newborns, and children. For
example, maternal health experts are particularly attuned to the
ways that pregnancy is a dynamic state that causes significant
physiological changes across gestation, while child health experts
may be particularly attuned to the implications for data interpreta-
tion of development changes in offspring, both pre- and post-birth.
Another reason for including maternal health experts in vaccine
research and development decisions is that obstetricians/gynecol-
ogists, midwives, and other women’s health practitioners will be
an important group in the deployment of vaccines to pregnant
women. Their willingness to endorse and participate in the immu-
nization of pregnant women may be enhanced if experts in their
fields have been involved in the development and testing of the
vaccine.
Recommendation 16
Whenever possible, the perspectives of pregnant women should be
considered in designing and implementing vaccine studies in
which pregnant women are enrolled or in which women enrolled
may become pregnant.
 Directed to: clinical investigators; vaccine developers; research
ethics committees; community advisory boards; funders and
sponsors; public health authorities
Community engagement and participatory-based approaches to
biomedical research have been increasingly recognized as good
practice in the design and conduct of human subjects research
[9,133,134]. The need for engagement is even more pronounced
during outbreaks and epidemics, a key lesson of the 2014 Ebola
experience [8,23].
In the context of vaccine studies enrolling pregnant women,
soliciting the perspectives of pregnant women from the communi-
ties in which the research will be conducted offers a way to
demonstrate respect, and can be critical to the success of a study.
The perspectives of pregnant women can also be important to var-
ious aspects of study design, including determining what informa-
tion and outcomes are most important to pregnant women,
ascertaining culturally relevant considerations for the consent pro-
cess, and establishing the appropriate frequency and location of
study visits based on the daily demands on women’s lives through-
out pregnancy and after delivery [8,135–137].
A number of resources provide guidance on how to engage com-
munities in biomedical research studies and the various approaches
to participatory-based research [10,134]. For example, one option is
to involve pregnant women in engagement platforms already being
planned for the research, such as a community advisory board.
Another option is to conduct dedicated formative research with
pregnant women or to establish an advisory board for the trial that
is composed of pregnant women and their family members.Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinBecause a number of standard protocols for vaccine efficacy tri-
als are being developed in advance of epidemics to enable rapid
implementation, there should be ample opportunity to engage
pregnant women as well as other stakeholders in the development
of these protocols [25,138,139].
Vaccine delivery during the epidemic response
Recommendation 17
Pregnant women should be offered vaccines as part of an outbreak
or epidemic response. Pregnant women should only be excluded if
a review of available evidence by relevant experts concludes that
the risks to pregnant women and their offspring from the vaccine
are demonstrably greater than the risks of not being vaccinated.
 Directed to: public health authorities; national immunization
programs; recommending and advisory bodies, including pro-
fessional medical associations, SAGE, and other relevant WHO
advisory committees; teams overseeing the epidemic response,
such as Public Health Emergency Operations Centers and inci-
dent management teams; organizations involved in vaccine
delivery in the outbreak response, including UNICEF, MSF, Inter-
national Federation of Red Cross
Because pregnant women are the moral equals of others, and
because there is nothing about being pregnant that would make
them or their offspring less susceptible to the harms of emerging
pathogenic threats, the default position of advisory bodies and
public health decision-makers should be that pregnant women
are offered vaccines alongside other affected populations dur-
ing an epidemic response. Any recommendations or decisions
not to use vaccines in pregnancy during an outbreak or epidemic
requires justification of exclusion based on a reasonable determi-
nation that the risks to pregnant women and their offspring from
vaccination are demonstrably greater than the likely benefits of
being protected from the pathogen.
An assessment of the comparative risks and benefits of vaccina-
tion in pregnancy during an outbreak should take into account the
same 6 considerations identified for the appropriateness of includ-
ing pregnant women in research: (1) the likelihood of infection; (2)
the likelihood and severity of harms to pregnant women and their
offspring from infection; (3) the likelihood that the vaccine will
protect against the potential risks of infection in both pregnant
women and their offspring; (4) the likelihood and severity of risks
to pregnant women and their offspring from receiving the vaccine;
(5) the availability of safe and effective alternative prevention
options; and (6) the availability of safe and effective treatment
options. However, at the time of implementing a vaccine cam-
paign, compared with the trial context, there is typically more evi-
dence available to inform these assessments. Table A provides
more detail about these considerations, with side-by-side compar-
isons of the two different contexts.
Risk-benefit assessments should be informed by expert review
of the best available evidence. The establishment of anWHO stand-
ing body of interdisciplinary experts dedicated to advising on vac-
cine use in pregnancy, as proposed for consideration in
Recommendation 6, can help fulfill this requirement. So, too, would
be the establishments of any regional or local counterparts.
The considerations in Table A are likely to play out differently
for different combinations of pathogenic threats and vaccine coun-
termeasures. Advisory committees, decision-makers, and the
experts they engage will need to weigh the evidence available at
the time as best they can to reach informed and fair judgments.
In some cases, there may be substantial data from intentional
administrations or inadvertent exposures during pregnancy inwomen & vaccines against emerging epidemic threats: Ethics guidance for
e.2019.01.011
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the safety of the vaccine in pregnant women. Alternatively, the
vaccine may be new but developed using a platform and/or
adjuvant that has been widely and safely used in other maternal
immunizations.
In other cases, it may be advantageous to offer pregnant women
vaccines with non-ideal characteristics for pregnancy because the
protective benefits of the vaccine outweigh risks. The absence of
evidence and the mere theoretical or even documented risk of
fetal harm is generally not sufficient to justify denying pregnant
women access to a vaccine in an outbreak or epidemic. Even
when the risk of fetal harm from the vaccine is significant, if
the likelihood and severity of harms from the pathogen are
high enough for pregnant women and their offspring, then
the benefits of vaccination may still outweigh the risks (see
Box 12). For example, while the live-attenuated yellow fever vac-
cine is not routinely offered to pregnant women, it is widely
endorsed for use during epidemics to protect pregnant women
and their offspring against the far greater risks of yellow fever
infection.Box 12. Theoretical risks of live vaccines in pregnancy versus
documented associated harms
Routine administration of live vaccines to pregnant
women has been generally contraindicated because of con-
cern for fetal harm [123,140]. However, not all live vaccines
pose equal concern. Concern is greatest for those live vac-
cines that replicate systemically and could potentially cross
the placenta. Despite unintended exposures during preg-
nancy to several of these types of live vaccines (e.g., rubella,
yellow fever, and smallpox vaccines) in hundreds to thou-
sands of women, convincing evidence of fetal harm has only
been demonstrated for smallpox vaccine (a small increased
risk of birth defects [2.4% vs. 1.5%] among women vaccinated
in the first trimester; a total of 21 cases of fetal vaccinia
reported in the literature) [119,123,141–145]. For this reason,
offering yellow fever and smallpox vaccines to pregnant
women at high risk of infection has been advised, based
upon the assessment that potential benefits far outweigh
risks [108,123]. When novel live vaccines are being developed
for emerging pathogens, it will be impossible to prospec-
tively assess the risk of fetal harm through transplacental
transmission of live-attenuated vaccine candidates that repli-
cate systemically. To ensure that pregnant women have
access to vaccines with reassuring safety data, investments
should be made in vaccine candidates that are most likely
to be acceptable in pregnancy (Recommendations 7 and 8). In
addition, since situations will likely arise in which women
are unintentionally exposed to these types of live vaccines
during pregnancy, it will be critical to systematically collect
data on pregnancy-specific indicators of safety to inform a
risk-benefit assessment (Recommendations 12 and 22).Consider also the rVSV-ZEBOV Ebola vaccine. This vaccine
would likely not be viewed as appropriate for use in pregnancy
outside the context of an Ebola outbreak. Currently, however, it
is the only Ebola vaccine that has successfully completed efficacy
trials [146]. Given the harms associated with Ebola infection in
pregnancy, including maternal mortality ranging from 70 to 90%
and near 100% fetal demise, the potential benefits of offering the
vaccine clearly outweigh the potential harms in the context of a
high incidence outbreak setting [2,3].Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinRecommendation 18
When there is a limited supply of vaccine against a pathogenic
threat that disproportionately affects pregnant women, their off-
spring, or both, or when only one vaccine among several is appro-
priate for use in pregnancy, then pregnant women should be
among the priority groups to be offered the vaccine.
 Directed to: public health authorities; national immunization
programs; teams overseeing the epidemic response, such as
Public Health Emergency Operations Centers and incident man-
agement teams; WHO; organizations involved in vaccine deliv-
ery as part of the outbreak response, including UNICEF, MSF,
International Federation of Red Cross
It is not uncommon in outbreak and epidemic settings for vac-
cine demand to exceed supply. Numerous groups have proposed
criteria for determining how to ethically set priorities among dif-
ferent groups of potential vaccine recipients [147–150]. Most
acknowledge that groups who face greater risk of harm from the
infection have a greater claim on vaccines than those who face les-
ser risks. For some pathogenic threats, such as Lassa fever, preg-
nant women and their offspring may be among the hardest hit
groups and should, like any other high-risk group, be a priority
in the allocation of a vaccine that is in short supply.
An additional argument in favor of placing a priority on preg-
nant women in vaccine scarcity settings is that vaccinating a preg-
nant woman protects not only the pregnant woman but also her
offspring. Particularly for high-consequence pathogens with signif-
icant mortality rates, there may be considerable benefit in vacci-
nating pregnant women. It is not only their lives, but the lives of
the children they bear that stand to be saved. This argument
applies even when the threat is no worse for pregnant women than
it is for other affected population groups.
Yet another context where pregnant women may justifiably be
made a priority is when more than one vaccine is available to com-
bat an outbreak or epidemic, but one vaccine is distinctly prefer-
able for use in pregnancy. Here, it may be appropriate to allocate
the preferable vaccine first for administration to pregnant women,
as well as to any other group who might benefit from that vaccine’s
specific characteristics.
As is the case with all allocation criteria for scarce resources in a
public health emergency, the reasons why some groups are prior-
itized should be communicated clearly to the public. Transparency
is crucial to sustaining public trust during epidemics [8,10,23].
Recommendation 19
When vaccines are offered to pregnant women in outbreaks or epi-
demics, prospective observational studies should be conducted
with pregnant women and their offspring to further advance the
evidence base for use in pregnancy.
 Directed to: vaccine manufacturers; public health and regula-
tory authorities; national immunization programs; organiza-
tions involved in vaccine delivery as part of the outbreak
response, including UNICEF, MSF, International Federation of
Red Cross; researchers; funders; groups that oversee research
with human subjects, including research ethics committees
Some vaccines will be offered to pregnant women during out-
breaks and epidemics even when little pregnancy-specific data
about the safety of the vaccine are available. When this occurs,
an important opportunity emerges to narrow the evidence gap
between pregnant women and other population groups by
implementing prospective observational studies of pregnant
women and their offspring who receive the vaccine as part of
the outbreak or epidemic response. If such studies are not con-women & vaccines against emerging epidemic threats: Ethics guidance for
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be faced with the same evidence gap as current decision makers
– an unacceptable outcome from both an equity and a public
health perspective. Moreover, safety data obtained from evaluat-
ing a vaccine derived using a novel platform in pregnant women
may inform future decision-making regarding the suitability of
that platform for the development of vaccines against other
pathogens.
Other vaccines will be recommended for use in pregnancy dur-
ing outbreaks or epidemics based on more robust evidence about
the safety of the specific vaccine product or vaccine platform. How-
ever, even in the best of cases, this evidence will be incomplete and
likely considerably less than what is available for other population
groups. Only relatively small numbers of pregnant women can
receive vaccines in clinical trial contexts. In contrast, when preg-
nant women are included in the population recommended to
receive vaccines in outbreak and epidemic contexts, large numbers
of pregnant women and their offspring are involved and can be fol-
lowed, generating much needed additional data.
There are a range of approaches that can be used to generate
evidence about the safety and efficacy of vaccines in pregnancy
from programmatic use in an outbreak or epidemic. These include
adverse event reporting systems, post-marketing surveillance, and
pregnancy registries. However, the best approach for gathering the
most relevant evidence is to conduct a prospective observational
study that has been planned in advance and is properly resourced.
If carefully designed, executed, and analyzed, post-authorization
studies can provide critical information for the optimal and appro-
priate use of vaccines in pregnancy.
In some cases, regulatory authorities can request or require
that sponsors conduct phase 4 studies. For instance, the U.S.
FDA can require sponsors to conduct additional post-approval
studies or trials for products approved under the accelerated
approval pathway to further demonstrate clinical benefit. They
can also require post-market assessments of risk signals orBox 13 Resources for conducting post-authorization observa-
tional studies with pregnant women
The European Medicines Agency (EMA) includes in their
Good Pharmacovigilance Practices (GVP) a ‘‘Guideline on
the exposure to medicinal products during pregnancy: Need
for post-authorisation data” and the Agency plans to release
a new population-specific chapter for Pregnant and Breast-
feeding Women for public consultation in late 2018 [151].
Similarly, the FDA provides general guidance for industry
on post-marketing studies and clinical trials – with an
updated draft guidance document currently under review
[13,152]. An article authored by GlaxoSmithKline employees
provides a manufacturer’s perspective on how to strengthen
post-authorization safety studies (PASS) of vaccines, which
included a description of a study prospectively designed to
assess the safety of the ASO3-adjuvanted H1N1 influenza
vaccine in pregnant women [153]. Other resources specific
to generating and harmonizing safety data for vaccines in
pregnancy—including in phase 4 studies—are available from
the GAIA project and The Brighton Collaboration (see Appen-
dix C). These resources and guidelines should be leveraged in
developing post-authorization studies and pharmacovigi-
lance plans for vaccines for outbreak and epidemic contexts
to help generate the best possible evidence on the safety
and efficacy of these vaccines in pregnancy. The prospective
study of killed oral cholera vaccine in Malawi provides an
illustrative example of how these post-authorization studies
can be conducted, and the advantages that a prospective
design offers over retrospective studies [154–156].
Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinknown serious risks associated with a product [152]. Similarly,
the European Medicines Agency has a variety of post-
authorization measures that can be requested or required
[157]. These include specific obligations that can be imposed
for products approved with conditional marketing authoriza-
tions, a pathway potentially available in emergency situations
[158]. Other national regulatory authorities may also have provi-
sions for requesting or requiring post-market research. When-
ever possible, these and other regulatory requirements should
be leveraged to support development of an adequate evidence
base for vaccines in pregnancy (see Box 13).Recommendation 20
When vaccines are offered to pregnant women in outbreaks and
epidemics, the consent of the pregnant woman should be sufficient
to authorize administration whenever the pregnant woman is of
legal standing to consent to medical care.
 Directed to: public health authorities; national immunization
programs; teams overseeing the epidemic response, such as
Public Health Emergency Operations Centers and incident man-
agement teams; organizations involved in vaccine delivery as
part of the outbreak response, including UNICEF, MSF, Interna-
tional Federation of Red Cross; clinicians and obstetricians;
pregnant women and communities
As noted in Recommendation 14 and elsewhere in this Guidance,
pregnant women are the moral equals of other self-governing
adults. As a matter of respect and as a key aspect of ensuring fair
access to vaccines during an outbreak or epidemic, when vaccines
are offered to pregnant women, their consent should be sufficient
to authorize administration.
Women should be presumed to be the proper locus of authority
for decisions about their own medical care. Women are no differ-
ent from men in this respect, and pregnant women are no different
than women who are not pregnant. All adults, regardless of gender
or pregnancy status, have rights of self-determination over deci-
sions that affect their bodies and their health.
There are a few jurisdictions and several cultures that do not
accept this premise, and require the authorization of husbands,
fathers, or other authority figures instead of or in addition to the
consent of the woman for medical interventions [159]. Public
health and clinical professionals may be legally obligated to follow
this practice. Even where it is prevailing custom rather than law
that imposes the requirement, it may be prudent to follow the
practice if that is the best way in an outbreak or epidemic to ensure
that pregnant women and their offspring, and women generally,
benefit from the protective effects of the vaccine. However, public
health and clinical professionals should challenge the practice of
requiring additional authorizations beyond that of the pregnant
woman whenever it is possible to do so without compromising
the preferences of pregnant women or the near-term health
and safety interests of pregnant women and their offspring.
Regardless of whether prevailing law and custom respect the
decisional authority of pregnant women, public health and clinical
professionals should also respect the preferences of pregnant
women who wish to engage their partners or other family or
friends in decisions about vaccination.
There may be epidemic contexts where the threat is so great
and the transmissibility so high that it is ethically justifiable to
relax or even suspend consent requirements for vaccine adminis-
trations, particularly when the vaccine deployed is licensed or reg-
istered. Under these circumstances, pregnant women should be
treated no differently from other self-governing adults who are
also targets for vaccination.women & vaccines against emerging epidemic threats: Ethics guidance for
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Box 14. Active and passive vaccine surveillance systems to
advance the evidence base on vaccines in pregnancy
Existing vaccine surveillance programs for monitoring
adverse events following immunization (AEFI) can be useful
tools to study both intentional and unintentional vaccine
administrations in pregnancy (Recommendations 19 and 22).
Various countries and regions have mandatory requirements
for passive reporting of any adverse events potentially asso-
ciated with immunization, including the U.S. Vaccine Adverse
Event Reporting System (VAERS), the EU EudraVigilance,
and the Chinese National AEFI Information System (CNAE-
FIS). Although the ability to draw conclusions from passive
surveillance systems is limited due to potential reporting bias
and unknown denominators, these systems can serve as
important mechanisms to identify safety signals for vaccina-
tion in pregnancy that require further study. They are espe-
cially useful and cost-effective for monitoring vaccines over
the longer term, enabling the detection of rare adverse events
that may occur in a very small percent of the vaccinated
population. These passive surveillance systems can be lever-
aged to enhance the evidence base on vaccine use in preg-
nancy by adding more targeted questions about pregnancy
status, gestational timing of immunization, and pregnancy-
specific outcomes to the data collection forms.
For newer vaccines, active surveillance mechanisms can
be critical tools to build upon pre-licensure safety data once
the vaccine is introduced to the broader population, without
some of the methodological shortcomings inherent in pas-
sive systems. In the U.S., various active vaccine surveillance
programs such as the Post-Licensure Rapid Immunization
Safety Monitoring (PRISM), Vaccines and Medications in
Pregnancy Surveillance System, and Vaccine Safety Datalink,
are being used to build the safety profile of vaccines in preg-
nancy [164–166]. The example of PRISM also highlights the
potential benefits of strengthening health information sys-
tems and how growing use of electronic medical records
can enhance post-market studies — including those focused
on safety in pregnancy. In recent years, there has been
increasing focus on the systematic surveillance for AEFI for
pregnant women and their offspring [167–170]. A recent glo-
bal survey identified 11 active surveillance systems across
countries in various income brackets and geographic regions
to detect serious AEFI in pregnant women or their infants,
with 4 of these systems specifically focused on inadvertent
vaccine administrations in pregnancy [169].
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permitted to authorize medical interventions, including vaccina-
tions, without parental consent. Some jurisdictions may recognize
pregnant young people as sole medical decision-makers at an ear-
lier age than non-pregnant minors. Also, in an epidemic context,
jurisdictions may relax parental consent requirements for vaccines
and other countermeasures as part of an emergency response.
Recommendation 21
When evidence supports a determination that the risk of serious
maternal or fetal harm from the vaccine outweighs the vaccine’s
benefits, pregnant women should be a priority group for access
to alternative preventative or treatment measures.
 Directed to: public health authorities; teams overseeing the
epidemic response, such as Public Health Emergency Opera-
tions Centers and incident management teams; organizations
involved in vaccine delivery as part of the outbreak response,
including UNICEF, MSF, International Federation of Red Cross;
providers
Despite the best possible research and development efforts, the
available vaccine for a given outbreak or epidemic may have suffi-
ciently severe pregnancy-specific risks, even compared to the risks
posed by the pathogen, that the vaccine is not made available to
pregnant women. The moral objective remains, however, of giving
pregnant women and their offspring as close to an equal chance of
avoiding the harms of infection as the rest of the population. If they
cannot be protected by immunization, then pregnant women,
along with any other population groups that cannot receive the
vaccine, should be given preferential access to alternative preven-
tive interventions and treatments.
The availability of alternative interventions that canmitigate the
harms of the pathogen, particularly those that have established
safety profiles in pregnancy, may be a significant factor in the judg-
ment that the vaccine risks to pregnant women and their offspring
outweigh the benefits.When this is the case, it is all themore impor-
tant that pregnant women be among other similarly situated popu-
lation groups in being prioritized for these alternative interventions.
Recommendation 22
When vaccines against emerging pathogens are not recommended
for use in pregnancy, inadvertent vaccine exposures during preg-
nancy should be anticipated and mechanisms put in place for the
collection and analysis of data from pregnant women and their off-
spring on relevant indicators and outcomes.
 Directed to: public health and regulatory authorities; vaccine
manufacturers; national immunization programs; funders and
sponsors
For most immunization efforts in response to outbreaks,
women of childbearing potential will comprise a significant subset
of the target population. Even when pregnant women are inten-
tionally excluded from the vaccine response effort, it should be
expected that some of the women who are vaccinated will be
unknowingly pregnant at the time of vaccine administration or will
become pregnant within a relevant window of its administration.
Collecting data about outcomes in these women and their offspring
in the midst of an active outbreak or epidemic will be difficult and
costly. However, there are two sets of ethical and public health rea-
sons why it is critically important to do so.
First, collecting data from unintentional exposures to vaccines in
pregnancy during an outbreak or epidemic affords an important
opportunity to gather evidence about novel vaccine technologies
and thus to help ensure that pregnant women are not left behindPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinas vaccine technology advances. Gathering data from women who
are unknowingly pregnant when they receive vaccines and subse-
quently from their offspring could be critical and uniquely informa-
tive to building an evidence base on safety and efficacy in
pregnancy of novel vaccine technologies, given that these data
may be difficult to otherwise obtain. For example, studies of oral
cholera vaccines given to women unintentionally during pregnancy
in Bangladesh, Guinea, Malawi, and Zanzibar were instrumental in
establishing the safety profile of the vaccine in pregnancy and shift-
ing the WHO recommendation in support of including pregnant
women in oral cholera vaccine campaigns [160].
The second set of reasons has to do with the importance of hav-
ing evidence for both personal and clinical decision-making about
the likelihood and nature of any risks to pregnant women or their
offspring associated with vaccine administration in early preg-
nancy. Research and public health communities have a responsibil-
ity to pursue evidence that will allow for the best possible
counseling on the implications of unintentional exposures during
pregnancy. The price of ignorance in the face of unintended expo-
sures is significant. We know from the experience with live-women & vaccines against emerging epidemic threats: Ethics guidance for
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28 C.B. Krubiner et al. / Vaccine xxx (xxxx) xxxattenuated rubella vaccines that hundreds of women inadvertently
exposed during pregnancy chose to terminate their pregnancies,
presumably due to concerns about unknown fetal harm [74,161–
163]. Yet worries about vaccine-associated congenital rubella
syndrome turned out to be unfounded, with not a single case doc-
umented from thousands of unintentional exposures worldwide
[123]. Furthermore, pregnant women who are vaccinated prior to
finding out they are pregnant will want to know not just whether
the vaccine is safe, but how likely it is that the vaccine they
received will protect them and their fetus from infection. Such
information may guide decisions about how aggressively to pursue
other protective measures and whether they should receive
another dose of vaccine after delivery to ensure protection in
future epidemics (see Box 14).
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EXCLUSION OF PREGNANT WOMEN FROM BIOMEDICAL
RESEARCH AGENDAS, & PRINCIPLES FOR ETHICAL INCLUSION
Any analysis of vaccine development and the needs and inter-
ests of pregnant women must take account of the complex and
rapidly evolving approach to maternal immunizations, the dangers
of delaying accrual of an evidence base for biomedical interven-
tions during pregnancy, and emerging consensus on ethical princi-
ples governing research with pregnant women.
Maternal immunization
Maternal immunization can offer significant benefits in a variety
of ways [171,172]. Some vaccines primarily serve to protect the
pregnant woman from seriousmorbidity ormortality. This includes
cases where pregnant women are one among many at-risk popula-
tions facing exposure to a virulent pathogen (e.g., yellow fever), as
well as cases where they face higher morbidity and mortality than
other population groups (e.g., influenza) [173–175]. In both
instances, offspring also benefit. Preventing disease in a pregnant
woman protects the fetus from the harms of maternal illness, in
utero exposures, and/or newborn exposures. Other maternal immu-
nizations are being developed primarily to prevent disease in new-
borns through passive transfer of maternal antibodies—respiratory
syncytial virus (RSV) and group B streptococcus (GBS) are examples
[7,19]. Still others, such as Zika virus vaccines, occupy a middle
ground. Their primary purpose is to protect the fetus, but the target
population is not exclusively pregnant women, and the vaccines
will offer direct benefits to adults, such as, in this case, protection
against virus-related risks of Guillain-Barré Syndrome (GBS).
Despite the important role that maternal immunizations can
play in preventing disease, there has historically been resistance
to vaccinating women during pregnancy [176,177]. However, the
critical importance of maternal immunization is now increasingly
recognized. In recent years, several National Immunization Techni-
cal Advisory Groups (NITAGs) and professional organizations in
high-income countries have recommended that pregnant women
receive inactivated influenza vaccine and tetanus, diphtheria, acel-
lular pertussis (Tdap) vaccines [140,178,179]. WHO now recom-
mends the use of the yellow fever vaccine during pregnancy in
outbreak contexts, even though it is a live-attenuated vaccine with
precautions issued for use in pregnancy [175]. Other vaccines have
been endorsed for use in pregnancy when there is a threat of expo-
sure (e.g., hepatitis A and B, meningococcus, Japanese encephalitis)
or as a post-exposure prophylaxis (e.g., anthrax, rabies, smallpox)
[173]. Still other vaccines, such as maternal vaccines for RSV and
GBS, are being developed that are specifically intended for preg-
nant women [171,180]. Because pregnant women are the only tar-Please cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccingets for these vaccines, the pathways to development and licensure
necessarily include research with pregnant women and require the
generation of evidence specific to their use in pregnancy [173,181].
The evidence gap for pregnant women
Most preventives and treatments developed for the general
population lack evidence to guide decisions about their use in
pregnancy. This problem has been particularly well characterized
in the context of drug treatment in the U.S.: data are insufficient
to determine teratogenic risk for more than 98% of drugs approved
by the U.S. Food and Drug Administration (FDA) since 2000, and
91% of drugs approved since 1980 [182,183]. For nearly three-
quarters of drugs approved since 2000, there are no human preg-
nancy data whatsoever. Similarly, information to guide drug dos-
ing is sorely lacking: more than 98% of pharmacokinetic studies
done provide no data specific to use in pregnancy [182,183].
The dearth of evidence is due to many factors. One is the com-
mon practice of waiting to conduct reproductive toxicology, muta-
genicity, and related studies until late in the R&D process when it is
likely that the drug or biologic will proceed to licensure. This prac-
tice is an effective cost-management strategy but results in unin-
tended downstream delays in understanding how the
intervention works in pregnancy. Preclinical data are often critical
to determinations of likely research-related risks and benefits of
the intervention and are required by most drug approval agency
guidance if pregnant women are to participate in drug develop-
ment clinical trials [184]. These data also help to identify areas of
potential concern or interest that should be pursued in research
to further assess safety in pregnancy [185].
In large part, though, the lack of evidence to inform the use of
preventives and treatments during pregnancy stems from a histor-
ical reticence to conduct interventional biomedical research with
pregnant women. Furthermore, the past practice in research over-
sight policies of categorizing pregnant women as ‘‘vulnerable”
encouraged the view that the proper ethical stance towards
research with pregnant women was exclusion, rather than careful
and thoughtful inclusion [10]. Other causes for this reticence
include misinterpretations or overly cautious interpretations of
what is allowed under research regulations and international
norms, as well as concerns about legal liability [85,186]. There
are a range of cultural norms surrounding pregnancy and gender
dynamics that complicate the involvement of pregnant women in
research in various contexts. Pharmaceutical companies face disin-
centives relating to liability exposure, not only for trial-related
risks but also post-approval liability that can be triggered if an
indication is sought for use of an intervention in pregnancy
[85,172,187]. Finally, there are a number of risk distortions that
have been noted with pregnancy, including, critically, the tendency
to overweight the potential research-related risks to the fetus
while ignoring the risks to the offspring of not allowing the preg-
nant woman into a study [188–190].
For all of these reasons, pregnant women have been treated dif-
ferently and, we have argued, unfairly in the development of new
drugs and biologics [189,191,192]. In contrast to other adults, little
if any evidence about safety and efficacy of these products for preg-
nant women is available at the time of licensure. It is only well
after licensure that evidence is usually generated, typically from
clinical experience or passive surveillance systems [193–196].
Reliance on registries and other passive post-marketing sys-
tems is problematic. Selection biases in passive surveillance favor
reporting of negative outcomes, and reports of adverse events
may be incomplete [195–198]. Although these systems are
designed only to surface safety signals requiring further investiga-
tion, not to draw scientific conclusions, signals are sometimes
over-interpreted as definitive evidence that a drug or biologicwomen & vaccines against emerging epidemic threats: Ethics guidance for
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Box A. Prospect vs. no prospect of direct benefit
Trials involving the prospect of direct benefit—some-
times called ‘‘therapeutic research”—are those in which the
study intervention may directly benefit the research partici-
pant. There is only a prospect of direct benefit, both because
there is not yet confirmation of efficacy (that being one of
the points of clinical research), and because, for trials with
control arms, a given participant may not receive the experi-
mental treatment being studied or an alternative intervention
of proven benefit.
In contrast, studies with no prospect of direct benefit are
those in which the possibility of benefit cannot reasonably be
attributed. These studies include many early phase trials in
which researchers have intentionally minimized the study
intervention dose as a strategy to answer specific questions
about safety, trials marked by too little evidence to reach a
threshold of any reasonable prospect of benefit (even if ben-
efits do accrue during the study), and studies whose focus is
to better understand a point of biology rather than to test a
potential preventive or therapeutic intervention. With studies
that have no prospect of direct benefit, enrollment is purely
for the value of advancing biomedical knowledge to the
potential benefit of future populations and patients.
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on passive systems can lead to long delays in safety determination.
In the US, it is estimated that the mean time it takes to assign a
pregnancy-specific risk level to drugs with undetermined risk at
the time of FDA approval is 27 years [182].
An increasing number of organizations, including WHO, PAHO,
CIOMS, ACOG, and the NIH Office of Research on Women’s Health
now recognize the importance, both scientifically and ethically, of
involving pregnant women in research [8–11,200,201]. They call
for a shift to integrating pregnant women into the research agenda,
while recognizing that research with pregnant women poses
unique ethical complexities because of risks and potential benefits
to future offspring who cannot consent for themselves. These orga-
nizations point out the analogy with and lessons from research
with children: the need to include their distinct needs in the
research agenda; the fact that there can be pathways to responsi-
ble inclusion; that access to trials involving the prospect of direct
benefit can be important as a matter of justice; and the imperative
to protect groups through research, not just from research.
Ethical principles for pregnant women and biomedical research
As the importance of including pregnant women more ade-
quately in the biomedical research agenda has solidified, four prin-
ciples guiding research ethics for pregnancy have emerged as a
growing consensus.
1. Pregnant women deserve an evidence base for the preven-
tion and treatment of their illnesses equal to others as a
matter of justice.
The foundational justification for this principle rests on the
recognition that, because pregnant women are the moral equiva-
lents of all other human beings and have equal moral standing,
their interests and needs deserve to be treated fairly in the public
investment in research. This principle has been reaffirmed in mul-
tiple international contexts, most recently by CIOMS in its explica-
tion of what equitable access to the benefits of research entails:
‘‘Equity in the distribution of the benefits of research requires that
research not disproportionately focus on the health needs of a lim-
ited class of people, but instead aims to address diverse health
needs across different classes or groups. . . . Since information
about the management of diseases is considered a benefit to soci-
ety, it is unjust to intentionally deprive specific groups of that ben-
efit.” [10] CIOMS explicitly includes pregnant women as such a
group.
Just allocation of research investments to the health needs of
pregnant women is also in accordance with a core commitment
of public health ethics to prioritize the needs of disadvantaged
groups and to diminish health disparities [202–204]. Illness in
pregnancy often brings increased risk of disease related-harms
for both the pregnant women and any resulting children, especially
among the global poor [205–207].
2. Pregnant women should not be categorized as a ‘‘vulnerable
population” for purposes of human subjects research review.
Until recently, pregnant women had been categorized as a ‘‘vul-
nerable population” for purposes of research regulations and guid-
ance. This included, influentially, the US Federal Policy for the
Protection of Human Subjects, which designated pregnant women
as vulnerable alongside those whose capacity to make valid deci-
sions about research participation is compromised, such as chil-
dren and adults of limited cognitive ability [11,208]. It was
increasingly realized that such a designation was problematic, tac-
itly suggesting that pregnant women are incapable of offering validPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccinconsent [128,209,129]. Further, the designation had unintended
consequences of increasing health burdens: rather than safeguard-
ing pregnant women and their future children from risk, it is now
widely recognized that the categorization had the perverse result
of adding risk to them by limiting the possibility of responsible
research into their potentially distinctive health needs.
Both CIOMS and the Federal Policy for the Protection of Human
Subjects have been recently updated to acknowledge that preg-
nancy itself does not make a woman ‘‘vulnerable” in the context
of research participation. The revised 2016 CIOMS guidelines
explicitly state that ‘‘pregnant women must not be considered vul-
nerable simply because they are pregnant,” and the recently
adopted updates to the Federal Policy for the Protection of Human
Subjects confirm ‘‘the final rule no longer includes pregnant
women. . . as examples of populations that are potentially vulnera-
ble to coercion or undue influence,” anticipated to go into effect
January 21, 2019 [10,127].
3. It is ethically permissible to conduct research with pregnant
women that meets specific risk standards.
Like any research involving human subjects, research with
pregnant women must meet all standard research protections: risk
must be the least needed for scientific purposes, for instance, and
appropriate informed consent must be obtained before research
proceeds. Because it involves implications for potential offspring,
there is widespread agreement that responsible research with
pregnant women also requires added levels of distinct oversight
for it to proceed [10,13]. Most centrally are specific standards of
what research-related risk is acceptable, especially to the fetus
and future child, who cannot consent to those risks.
There are two different standards, depending on whether the
trial in question offers the prospect of direct benefit to participants
or offspring (see Box A).For trials that involve no prospect of direct benefit to either the
woman or the future child, research-related risks to the future
child are capped at a low risk threshold. In general, trials that do
not carry any prospect of direct benefit to either the fetus or the
pregnant woman can pose no more than ‘‘minimal risk” to thewomen & vaccines against emerging epidemic threats: Ethics guidance for
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bility and magnitude of anticipated harms with those ordinarily
encountered in daily life or during the performance of routine
physical or psychological examinations or tests [10,127]. Excep-
tions are given for research involving particularly compelling
needs for the population of pregnant women and their infants:
CIOMS allows a ‘‘minor increase over minimal risk” and the
Department of Health and Human Services (HHS) regulations carry
a provision of increased risk under special HHS Secretarial review
[10,127]. While research involving no prospect of direct benefit
to woman or future child can be important, it is not generally at
issue in pregnancy and vaccine research.
For trials offering the prospect of direct benefit to the pregnant
woman, offspring, or both, the standard of acceptable risk is impor-
tantly different. Rather than a specific threshold, acceptable risk is
determined by the reasonability of the relation of research-related
risks to the potential benefits offered by participation [210]. The
risk is justified by the potential benefits to the subjects. More
specifically, the likelihood and importance of the potential benefits
must be reasonably judged to outweigh the risks. These potential
benefits must be at least as good as any available alternative pre-
ventive or therapeutic, as judged by a credible interpretation of
available evidence, understanding that all such determinations will
involve contexts of uncertainty [10].
There is no settled view about whether the prospect of benefit
to the pregnant woman alone can justify an increment of
research-related risk to the fetus. Important questions thus remain
about how to proceed when interpreting acceptable fetal risk in
research that carries the prospect of clinical benefit to the woman
but not to the fetus. These questions are generally less likely to
arise in vaccine research around emerging pathogens, because both
the pregnant woman and her offspring are likely to benefit from
maternal vaccination in these contexts. In these kinds of cases,
there is clear agreement that research that has a favorable poten-
tial risk-benefit balance (see Box B) to the fetus can proceed so long
as other protective regulatory standards are met.Box B. Reasonable judgments of favorable risk-benefit
balance
Reasonable judgments of favorable risk-benefit balance
entail credible interpretation of available evidence that the
probability and magnitude of research-related risks is out-
weighed by the probability and magnitude of prospective
benefit.4. Justice requires that pregnant women have fair access to
research that offers the prospect of direct benefit.
Thedistinction between research involving the prospect of direct
benefit and those that do not is also key to understanding another
implication of the demands of justice as a core principle of research
ethics; the importance of fair access to participate in research
involving theprospect of direct benefit [192,211,212]. There is broad
consensus thatwhile biomedical research ethics includes the ethical
imperative of protection from research harms and risks, it also
includes the ethical imperative of fair opportunity to the benefits
that participation in research can offer. Inclusion criteria for who
is eligible for enrollment in research that offers a prospect of benefit
must not unfairly exclude any group of persons or individual.
Fair opportunity to access the potential benefits of research par-
ticipation stands as a critical ethical principle of justice that cannotPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant
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where it may not be scientifically necessary to include pregnant to
generate valid conclusions on the use of a product in pregnancy,
pregnant women may still have compelling claims to participate in
trials that offer the prospect of direct benefit to them or their off-
spring. This may be particularly true in the case of emerging infec-
tious diseases and public health emergencies, when there are often
few if any alternatives available for pregnant women to protect
and preserve their health and that of their future offspring.
Fair access does not mean an automatic right to enrollment in all
research involving the prospect of direct benefit. If a subpopulation
does not meet the scientific eligibility requirements, or the risks of
the trial are not in proportion to benefits for the group, then their
exclusion is justified. Instead, fair access requires that a groupmust
be judged eligible to participate so long as it meets general criteria
of scientific relevance; that participation is otherwise allowable
under applicable regulations and ethics guidance, including that
there is a reasonable judgment of benefit favorable to risk; and that
cost considerations do not suffice as a justification for exclusion.
Regulatory commentary and scholars in research ethics make
clear that pregnant women are no exception to this principle
[10,192,211,212]. Pregnant women do not forfeit due considera-
tion of how their health and interests could be advanced by partic-
ipation in research simply because they are pregnant. More than
that, in a great many cases, including vaccine research, the benefits
at stake with pregnant women’s inclusion are benefits that accrue
to two entities, not just one: the woman herself, as well as her off-
spring. The greater the potential benefits at stake in participation,
the more important it is not to exclude a class of persons who are
otherwise eligible for inclusion.
Pregnant women are also entitled to treatment equal to other
adults with regard to authorization of research participation. Fair
access to research that offers a prospect of direct benefit requires
that only the informed consent of the pregnant woman be soli-
cited, and that her consent, alone, is sufficient to authorize
research participation.APPENDIX B. PREVENT APPROACH TO GUIDANCE DEVELOPMENT
The Guidance was co-authored by the PREVENT Working
Group, a multi-disciplinary, international team of 17 experts spe-
cializing in bioethics, maternal immunization, maternal-fetal med-
icine, obstetrics, pediatrics, philosophy, public health, and vaccine
research and policy. Working Group members convened for one in-
person meeting over two days in February 2018 and participated in
multiple phone and video-conference discussions and email
exchanges to develop and refine the Guidance between July 2017
and August 2018.
Beyond the members of our Working Group, we relied on a
broad consultation strategy to ensure that the content of our rec-
ommendations was informed by wide-ranging areas of expertise
and the most-up-to-date information on evolving changes to the
epidemic vaccine development and deployment landscape.
The consultation strategy built upon previous engagement
efforts conducted between April 2016-June 2017 in support of
developing ethics guidance specific to Zika virus vaccines,
‘‘Pregnant Women & the Zika Virus Vaccine Research Agenda:
Ethics Guidance on Priorities, Inclusion, and Evidence Generation.”
For the development of the initial ZIKV Guidance, we conducted
consultations with more than 60 experts in bioethics, public
health, vaccine science and policy, obstetrics, maternal-fetal med-
icine, pediatrics, pharmaceutical development, and regulatory
affairs. A 15-person expert Working Group co-authored the ZIKV
Guidance, with many members continuing on to serve on the PRE-
VENT Working Group.women & vaccines against emerging epidemic threats: Ethics guidance for
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more than 40 additional experts, including those working in pre-
clinical and clinical vaccine development, regulatory affairs, vac-
cine policy – particularly as it pertains to vaccine delivery as part
of epidemic response, infectious disease epidemiology, maternal,
newborn, and child health, and bioethics. These experts come from
a wide range of institutions, including but not limited to public
health agencies and organizations at national, regional, and global
levels, academic institutions, non-governmental organizations that
conduct vaccine research and engage in vaccine implementation
efforts, global health funding organizations, and multilateral
donors. Many of those with whom we consulted had prior experi-
ence working in the pharmaceutical industry (both in ‘big pharma’
and in biotechnology companies).
Beyond targeted consultations with these diverse experts, we
shared various pieces and draft versions of the guidance document
at a number of presentations and roundtable sessions throughout
various stages of development. Meetings at which we presented
draft guidance materials include:
 Ethox Centre Ethical Design of Vaccine Trials in Emerging Infec-
tions Workshop (2017)
 Infectious Diseases Society for Obstetrics and Gynecology
(IDSOG) 2017 & 2018 Annual Meetings
 American Society for Bioethics and Humanities 2017 Annual
Conference
 The 2nd meeting of the U.S. HHS Task Force on Research Specific
to Pregnant Women and Lactating Women (PRGLAC)
 American Society of Tropical Medicine & Hygiene (ASTMH)
2017 Annual Meeting
 A half-day ASTMH satellite workshop hosted at Johns Hopkins
Berman Institute
 WHO Product Development for Vaccines Advisory Committee
(PDVAC) Consultation on Nucleic Acid Vaccines (February 2018)
 Interactive Roundtable at the 2018 World Vaccine Congress
 2018 Annual Conference on Vaccinology Research
We are grateful to all who shared their time and feedback with
the Working Group in support of this Guidance.
APPENDIX C. SELECT GAIA RESOURCES
The Global Alignment of Immunization safety Assessment in
pregnancy (GAIA) project was formed in response to a call from the
World Health Organization for a globally concerted approach to
actively monitor the safety of vaccines in pregnancy. GAIA aims
to improve the quality of outcome data from clinical vaccine trials
in pregnant women, with a specific focus on low- and middle-
income countries (LMICs), where the incidence of infectious dis-
eases is highest. The project – coordinated by the Brighton Collabo-
ration Foundation with core funding from the Bill & Melinda Gates
Foundation – seeks to improve data generated on immunization in
pregnancy by harmonizingmaternal, pregnancy, fetal, and neonatal
health outcome assessment. GAIA has published a number of
resources to this end, including in two special issues of the journal
Vaccine. These and other select publications are listed below for ref-
erence. Additional resources can be found on their website:
http://gaia-consortium.net/outputs/
-------
Kochhar S, Bauwens J, Bonhoeffer J, GAIA Project Participants.
Safety assessment of immunization in pregnancy. Vaccine.
2017 Dec 4;35(48Pt A):6469–6471.
Kochhar S, Bonhoeffer J, Jones CE, Muñoz FM, Honrado A, Bau-
wens J, Sobanjo-Ter Meulen A, Hirschfeld S. Immunization inPlease cite this article as: C. B. Krubiner, R. R. Faden, R. A. Karron et al., Pregnant wo
preparedness, research, and response, Vaccine, https://doi.org/10.1016/j.vaccine.2pregnancy clinical research in low- and middle-income coun-
tries - Study design, regulatory and safety considerations.Vac-
cine. 2017 Dec 4;35(48Pt A):6575–6581.
Bonhoeffer J, Kochhar S, Hirschfeld S, Heath PT, Jones CE, Bau-
wens J, et al. Global alignment of immunization safety assess-
ment in pregnancy—The GAIA project. Vaccine. 2016 Dec 1;34
(49):5993–7.
Chen RT, Moro PL, Bauwens J, Bonhoeffer J. Obstetrical and
neonatal case definitions for immunization safety data. Vaccine.
2016 Dec 1;34(49):5991–2.
Jones CE, Munoz FM, Kochhar S, Vergnano S, Cutland CL, Stein-
hoff M, et al. Guidance for the collection of case report form
variables to assess safety in clinical trials of vaccines in preg-
nancy. Vaccine. 2016 Dec 1;34(49):6007–14.
Jones CE, Munoz FM, Spiegel HML, Heininger U, Zuber PLF,
Edwards KM, et al. Guideline for collection, analysis and presen-
tation of safety data in clinical trials of vaccines in pregnant
women. Vaccine. 2016 Dec 1;34(49):5998–6006.
DeSilva M, Munoz FM, Mcmillan M, Kawai AT, Marshall H,
Macartney KK, et al. Congenital anomalies: Case definition
and guidelines for data collection, analysis, and presentation
of immunization safety data. Vaccine. 2016 Dec 1;34
(49):6015–26.
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Kapoor A, et al. Neonatal death: Case definition & guidelines for
data collection, analysis, and presentation of immunization
safety data. Vaccine. 2016 Dec 1;34(49):6027–37.
Vergnano S, Buttery J, Cailes B, Chandrasekaran R, Chiappini E,
Clark E, et al. Neonatal infections: Case definition and guidelines
for data collection, analysis, and presentation of immunisation
safety data. Vaccine. 2016 Dec 1;34(49):6038–46.
Tavares Da Silva F, Gonik B, McMillan M, Keech C, Dellicour S,
Bhange S, et al. Stillbirth: Case definition and guidelines for data
collection, analysis, and presentation of maternal immunization
safety data. Vaccine. 2016 Dec 1;34(49):6057–68.
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et al. Hypertensive disorders of pregnancy: Case definitions &
guidelines for data collection, analysis, and presentation of
immunization safety data. Vaccine. 2016 Dec 1;34(49):6069–76.
Quinn J-A, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore
T, et al. Preterm birth: Case definition & guidelines for data col-
lection, analysis, and presentation of immunisation safety data.
Vaccine. 2016 Dec 1;34(49):6047–56.
Patwardhan M, Eckert LO, Spiegel H, Pourmalek F, Cutland C,
Kochhar S, et al. Maternal death: Case definition and guidelines
for data collection, analysis, and presentation of immunization
safety data. Vaccine. 2016 Dec 1;34(49):6077–83.
Kerr R, Eckert LO, Winikoff B, Durocher J, Meher S, Fawcus S,
et al. Postpartum haemorrhage: Case definition and guidelines
for data collection, analysis, and presentation of immunization
safety data. Vaccine. 2016 Dec 1;34(49):6102–9.
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McClure EM, et al. Pathways to preterm birth: Case definition
and guidelines for data collection, analysis, and presentation
of immunization safety data. Vaccine. 2016 Dec 1;34
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